EP2616537A2 - Procédés et compositions pour le transport extracellulaire d'hydrocarbures biosynthétiques et autres molécules - Google Patents

Procédés et compositions pour le transport extracellulaire d'hydrocarbures biosynthétiques et autres molécules

Info

Publication number
EP2616537A2
EP2616537A2 EP11825898.7A EP11825898A EP2616537A2 EP 2616537 A2 EP2616537 A2 EP 2616537A2 EP 11825898 A EP11825898 A EP 11825898A EP 2616537 A2 EP2616537 A2 EP 2616537A2
Authority
EP
European Patent Office
Prior art keywords
microorganism
engineered
recombinant
alkanes
tolc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11825898.7A
Other languages
German (de)
English (en)
Other versions
EP2616537A4 (fr
Inventor
Nikos Basil Reppas
Carolyn Lawrence
Kevin Smith
Martha Sholl
Christian Perry Ridley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joule Unlimited Technologies Inc
Original Assignee
Joule Unlimited Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joule Unlimited Technologies Inc filed Critical Joule Unlimited Technologies Inc
Publication of EP2616537A2 publication Critical patent/EP2616537A2/fr
Publication of EP2616537A4 publication Critical patent/EP2616537A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/02—Preparation of hydrocarbons or halogenated hydrocarbons acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/02—Preparation of hydrocarbons or halogenated hydrocarbons acyclic
    • C12P5/026—Unsaturated compounds, i.e. alkenes, alkynes or allenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif

Definitions

  • This invention pertains to compositions and methods for increasing the amount of hydrocarbons (particularly «-alkanes and «-alkenes, but not limited to these compositions) that are secreted by engineered microorganisms which have been modified to biosynthetically produce such hydrocarbons.
  • the invention provides engineered microorganisms comprising recombinant enzymes for producing hydrocarbons, wherein said microorganisms are further modified to secrete said hydrocarbons in greater amounts than otherwise identical hydrocarbon-producing microorganisms lacking the modifications.
  • the invention also provides a recombinant multi-subunit prokaryotic efflux pump (YbhGFSR and functional homologs thereof) capable of mediating the export of intracellular «-alkanes and «-alkenes, e.g., «-pentadecane and «-heptadecene, generated by the concerted action of acyl-ACP reductase (AAR) and alkanal deformylative
  • YbhGFSR and functional homologs thereof capable of mediating the export of intracellular «-alkanes and «-alkenes, e.g., «-pentadecane and «-heptadecene, generated by the concerted action of acyl-ACP reductase (AAR) and alkanal deformylative
  • the invention provides a recombinant microorganism comprising recombinant alkane -producing enzymes described herein in addition to a
  • the invention provides methods of culturing such microorganisms, wherein said microorganisms secrete biosynthetic alkanes and/or alkanes into the culture medium.
  • the invention provides an engineered microorganism comprising a disrupted S layer or a disrupted glycocalyx, wherein said engineered
  • microorganism comprises (i) one or more recombinant genes encoding enzymes which catalyze the production of «-alkanes or «-alkenes, and (ii) a mutation in a gene involved in the biosynthesis or maintenance of said S layer or said glycocalyx, wherein said mutation leads to the disruption of said S layer or said glycocalyx.
  • the invention provides methods of culturing such microorganisms, wherein said microorganisms secrete biosynthetic alkanes and/or alkanes into the culture medium.
  • the invention provides an engineered photosynthetic microorganism, wherein said engineered photosynthetic microorganism comprises (i) one or more recombinant genes encoding enzymes which catalyze the production of «-alkanes, and (ii) one or more recombinant genes encoding an acetyl-CoA carboxylase.
  • the invention provides methods for producing hydrocarbons, comprising culturing such an wherein said engineered microorganism produces «-alkanes and/or «-alkenes, and wherein said engineered microorganism secretes increased amounts of «-alkanes and/or «-alkenes into the culture medium relative to an otherwise identical microorganism, cultured under identical conditions, but lacking said one or more genes encoding said acetyl-CoA carboxylase.
  • An engineered microorganism wherein said engineered microorganism comprises (i) one or more recombinant genes encoding enzymes which catalyze the production of alkanes, and (ii) one or more recombinant genes encoding one or more protein components of a recombinant hydrocarbon ABC efflux pump system.
  • ADM deformylative monooxygenase
  • ABC efflux pump system is selected from the group consisting of the ybhG/ybhF/ybhS/ybhR/tolC and the yhil/rbbA/yhhJ/tolC pump system.
  • microorganism is E. coli.
  • operon comprising ybhG/ybhF/ybhS/ybhR is controlled by a recombinant promoter, and wherein said promoter is constitutive or inducible.
  • microorganism is a photosynthetic microorganism.
  • YbhS and YbhR proteins or homologs thereof are selected from those listed in Table 20.
  • TolC or TolC homolog is an OMP variant from Table 20.
  • An engineered photosynthetic microorganism comprising a recombinant outer membrane protein and a recombinant complementary ABC efflux pump, wherein said recombinant outer membrane protein is SY PCC7002 A0585, and wherein said recombinant complementary ABC efflux pump comprises (i) a YbhG variant selected from Set 1 of Table 20, (ii) YbhF, and (iii) a YbhS/YbhR variant listed in Table 20. [0017] 21.
  • An engineered photosynthetic microorganism comprising a recombinant outer membrane protein and a recombinant complementary ABC efflux pump, wherein said recombinant outer membrane protein is selected from the group consisting of the OMP variants listed in Set 2 of Table 20, and wherein said recombinant ABC efflux pump comprises (i) a YbhG variant selected from Set 2 of Table 20, (ii) YbhF, and (iii) a YbhS/YbhR variant listed in Table 20.
  • a method for producing hydrocarbons comprising:
  • a method for producing hydrocarbons comprising:
  • microorganism further produces at least one «-alkene or «-alkanol.
  • microorganism produces at least one «-alkene or «-alkanol selected from the group consisting of «-pentadecene, «-heptadecene, and 1 -octadecanol. [0035] 36.
  • said «-alkanes comprise predominantly
  • At least one promoter is a urea- repressible, nitrate-inducible promoter.
  • a method for producing a hydrocarbon of interest comprising (i)
  • LPS LPS layer
  • said engineered microorganism comprises (i) one or more recombinant genes encoding enzymes which catalyze the production of «-alkanes, and (ii) a mutation in a gene involved in the biosynthesis or maintenance of said LPS layer, wherein said mutation leads to the disruption of said LPS layer.
  • a method for producing hydrocarbons comprising: culturing an
  • engineered microorganism of any of claims 49-53 in a culture medium wherein said engineered microorganism produces «-alkanes or «-alkenes, and wherein said engineered microorganism secretes increased amounts of «-alkanes or «-alkenes into the culture medium relative to an otherwise identical microorganism, cultured under identical conditions, but lacking said mutation in said gene involved in the biosynthesis or maintenance of said LPS layer.
  • said engineered microorganism is an engineered is. coli and wherein at least 10% of said «-alkanes or «-alkenes are secreted into the culture medium.
  • An engineered microorganism comprising a disrupted S layer or a
  • said engineered microorganism comprises (i) one or more recombinant genes encoding enzymes which catalyze the production of «-alkanes or n- alkenes, and (ii) a mutation in a gene involved in the biosynthesis or maintenance of said S layer or said glycocalyx, wherein said mutation leads to the disruption of said S layer or said glycocalyx.
  • microorganism is a cyanobacterium.
  • a method for producing hydrocarbons comprising: culturing an
  • engineered microorganism of any of claims 59-62 in a culture medium wherein said engineered microorganism produces «-alkanes or «-alkenes, and wherein said engineered microorganism secretes increased amounts of «-alkanes or «-alkenes into the culture medium relative to an otherwise identical microorganism, cultured under identical conditions, but lacking said mutation in said gene involved in the biosynthesis or maintenance of said S layer or said glycocalyx.
  • An engineered photosynthetic microorganism wherein said engineered photosynthetic microorganism comprises (i) one or more recombinant genes encoding enzymes which catalyze the production of «-alkanes, and (ii) one or more recombinant genes encoding an acetyl-CoA carboxylase.
  • ammonia-repressible nitrate reductase promoter is selected from the group consisting of p(nir07) and p(nir09).
  • a method for producing hydrocarbons comprising: culturing an
  • engineered photosynthetic microorganism of any of claims 64-71 in a culture medium wherein said engineered microorganism produces «-alkanes, and wherein said engineered microorganism secretes increased amounts of «-alkanes into the culture medium relative to an otherwise identical microorganism, cultured under identical conditions, but lacking said one or more genes encoding an acetyl-CoA carboxylase.
  • An isolated nucleic acid wherein said isolated nucleic acid comprises an engineered nucleotide sequence selected from SEQ ID NOs: 1 -214.
  • An engineered microbe wherein said engineered microbe comprises a recombinant nucleic acid or recombinant protein comprising a sequence selected from SEQ ID NO: 1-214.
  • the photosynthetic microbe is a cyanobacterium.
  • the invention also provides various nucleic acid constructs and/or vectors and associated methods for engineering the various microorganisms described herein.
  • FIG. 1 Hydrocarbon production by E. coli BL21(DE3) derivatives JCCl 169, JCCl 170, JCC1214, and JCCl 113.
  • #1 and #2 indicate the numbers of each of the two biological replicate cultures used for each strain.
  • Tl represents the time just before addition of 1 mM IPTG;
  • T2 represents a time 3.5 hr after Tl .
  • the fraction of total alka(e)ne for each of the JCC1214 and JCCl 113 T2 samples that was detected in the medium-associated extractant is indicated.
  • FIG. 2 The ybhGFSR genomic region in E. coli, encoding the components of the putative YbhGFSR ABC efflux pump for extruding hydrocarbons like n-pentadecane out of the cell.
  • ybhG encodes the membrane fusion protein (MFP)
  • ybhF encodes the ATP-hydrolytic subunit (also referred to herein as the ATP -binding subunit)
  • ybhS and ybhR encode the inner membrane subunits (also referred to herein as permease subunits).
  • Below the gene map are the fluorescence signals of the Agilent microarray probes corresponding to the gene above each bar graph (the y-axis is the probe fluorescence signal).
  • the first two bars represent JCCl 169 Tl and T2, respectively; the next two bars JCCl 170 Tl and T2, respectively; the next two bars, JCC1214 Tl and T2, respectively; the next two bars JCCl 1 13 Tl and T2, respectively.
  • Each bar has two sub-bars corresponding to the two replicate cultures of each strain, #1 and #2.
  • Figure 3 Sequence logo of the short loop sequence separating the coil-coiled helices in the following known E. coli MFS TolC-interactors: EmrA, EmrK, AcrA, AcrE, MdtE, MdtA, and MacA.
  • Figure 4 is a schematic depiction of the fully assembled YbhGFSR-TolC efflux pump.
  • Figure 5 depicts schematically the native ybiH/ybhG/ybhF/ybhS/ybhR operon (top) and a recombinant operon wherein ybiH is disrupted and the promoter of the operon is replaced.
  • Figure 6 shows the relative alkane production and secretion capabilities of various engineered is. coli strains that recombinantly express ADM and AAR enzyme activities.
  • Figure 7 shows alkane production and secretion by overexpression of ybhGFSR in E. coli JCC1880 expressing adm-aar.
  • Figure 8 shows production of pentadecane in the medium and cell pellets of
  • JCC2055 derived strains bearing the A0585_ProNTerm_tolC and ybhGFSR transporter. Data are also included from a control strain (JCC2055 1) which did not contain the transporter and produced a similar titre of pentadecane. The % of pentadecane in the medium is indicated above the bar for each strain.
  • Cyanobacteria contain not only a plasma membrane (PM) like non-photosynthetic prokaryotic hosts (as well as an outer membrane like their Gram-negative non-photosynthetic counterparts), but also, typically, an intracellular thylakoid membrane (TM) system that serves as the site for photosynthetic electron transfer and proton pumping.
  • PM plasma membrane
  • TM thylakoid membrane
  • HIPMPs heterologous integral plasma membrane proteins
  • the HIPMPs of interest comprise proteins that mediate transport, typically efflux, of substrates across the cyanobacterial plasma membrane.
  • HIPMPs of particular interest with respect to the efflux of «-alkanes and «-alkenes are the integral plasma membrane subunits, YbhS and YbhR, of a putative YbhGFSR-TolC efflux pump system from E. coli.
  • membrane proteins that are not HIPMPs, i.e., proteins that are derived from membranes other than the plasma membrane.
  • Such alternative membranes include: the thylakoid membrane, the endoplasmic reticulum membrane, the chloroplast inner membrane, and the mitochondrial inner membrane.
  • the disclosure provides methods for designing a protein comprising a pseudo-leader sequence (PLS) of defined sequence fused to the N-terminus of an HIPMP of interest, wherein the resulting chimeric protein is expressed in a cyanobacterial host cell, e.g., JCC138 (Synechocystis sp. PCC 7002) or an engineered derivative thereof.
  • a cyanobacterial host cell e.g., JCC138 (Synechocystis sp. PCC 7002) or an engineered derivative thereof.
  • the expression of the chimeric protein will increase the amount of hydrocarbon products of interest (e.g., alkanes, alkenes, alkyl alkanoates, etc.) exported from the cynanobacterial host cell.
  • the PLS encodes a contiguous polypeptide sub-fragment of a protein from a different thylakoid- membrane-containing cyanobacterial host, e.g., JCC160 (Synechococcus sp. PCC 6803), that localizes as uniquely as possible to the plasma membrane of that host.
  • JCC160 Synechococcus sp. PCC 6803
  • the mechanism that this non-JCC138 host natively employs to effect the localization of the protein to the plasma membrane should be conserved in order for the localization to occur in the recipient host.
  • PLSs are designed to ensure, or at least bias, the targeting of HIPMPs to the plasma membrane of the heterologous cyanobacterial host, they may not always be required. This is because sufficient levels of functional HIPMP may become embedded in the plasma membrane if the cyanobacterial host does, in fact, mechanistically recognize the protein as a native plasma membrane protein - even if some fraction of the protein is targeted to the thylakoid membrane or ends up in neither membrane (e.g., as inclusion bodies).
  • the PLS is derived from a plasma- membrane-resident protein that is naturally anchored in the membrane of a different cyanobacterial species (i.e. , different than the species into which the PLS will be functionally expressed) via two transmembrane a helices, and (ii) said plasma- membrane-resident protein naturally has its N-terminus within the cytoplasm and its C-terminus within the cytoplasm
  • the PLS is derived from a plasma-membrane-resident protein that is naturally anchored in the membrane of a different cyanobacterial species via one transmembrane a helix, and (ii) said plasma-membrane-resident protein naturally has its N-terminus within the cytoplasm and its C-terminus within the periplasm (N in /C out ).
  • PLSs are derived from host proteins that have most of their mass in either the periplasmic and/or cytoplasmic spaces.
  • said PLSs should contain only two a helices with Ni n / n topology (for creating ⁇ ; ⁇ HIPMPs) and only one a helix with Ni n /C out topology (for creating N out HIPMPs).
  • the potential for intermolecular homomultimerization among the transmembrane helices of the PLSs is minimized.
  • fused refers to the joining of one functional protein or protein subunit (e.g., a pseudo-leader sequence) to another functional protein or protein subunit (e.g., an integral plasma membrane protein). Fusing can occur by any method which results in the covalent attachment of the C- terminus of one such protein molecule to the N-terminus of another. For example, one skilled in the art will recognize that fusing occurs when the two proteins to be fused are encoded by a recombinant nucleic acid under control of a promoter and expressed as a single structural gene in vivo or in vitro.
  • non-target refers to a protein or nucleic acid that is native to a species that is different than the species that will be used to recombinantly express the protein or nucleic acid.
  • Alkanes also known as paraffins, are chemical compounds that consist only of the elements carbon (C) and hydrogen (H) (i.e. , hydrocarbons), wherein these atoms are linked together exclusively by single bonds (i.e., they are saturated compounds) without any cyclic structure.
  • C carbon
  • H hydrogen
  • alkanes are linear, i.e., unbranched, alkanes.
  • AAR or ADM enzymes are referred to herein as Aar genes iaar) or Adm genes (adm), respectively. Together, AAR and ADM enzymes function to synthesize n- alkanes from acyl-ACP molecules.
  • an AAR enzyme refers to an enzyme with the amino acid sequence of the SY PCC7942_1594 protein or a homolog thereof, wherein a SY PCC7942_1594 homolog is a protein whose BLAST alignment (i) covers >90% length of SYNPCC7942J594, (ii) covers >90% of the length of the matching protein, and (iii) has >50% identity with SY PCC7942_1594 (when optimally aligned using the parameters provided herein), and retains the functional activity of SY PCC7942_1594, i.e., the conversion of an acyl-ACP (acyl-acyl carrier protein) to an «-alkanal.
  • acyl-ACP acyl-acyl carrier protein
  • An ADM enzyme refers to an enzyme with the amino acid sequence of the SY PCC7942 1593 protein or a homolog thereof, wherein a SY PCC7942_1593 homolog is defined as a protein whose amino acid sequence alignment (i) covers >90% length of SY PCC7942_1593, (ii) covers >90% of the length of the matching protein, and (iii) has >50% identity with SY PCC7942_1593 (when aligned using the preferred parameters provided herein), and retains the functional activity of SY PCC7942_1593, i.e., the conversion of an «-alkanal to an ( «-l)-alkane.
  • Exemplary AAR and ADM enzymes are listed in Table 1 and Table 2, respectively, of U.S. utility application 12/759,657, filed April 13, 2010 (now U.S. Pat. No. 7,794,969), and U.S. utility application 12/833,821 , filed July 9, 2010.
  • Other ADM activities are described in U.S. Pat. App. No. 12/620,328, filed November 17, 2009.
  • this enzyme was referred to as an alkanal decarboxylative monooxygenase.
  • the protein is referred to herein as an alkanal deformylative monooxygenase or abbreviated as ADM; to be clear, it is the same protein referred to in the related applications.
  • Preferred parameters for BLASTp are: Expectation value: 10 (default); Filter: none; Cost to open a gap: 1 1 (default); Cost to extend a gap: 1 (default); Maximum alignments: 100 (default); Word size: 1 1 (default); No. of descriptions: 100 (default); Penalty Matrix:
  • Functional homologs of other proteins described herein may share significant amino acid identity (>50%) with the named proteins whose sequences are presented herein.
  • Such homologs may be obtained from other organisms where the proteins are known to share structural and functional characteristics with the named proteins. For example, a functional outer membrane protein that is at least 95% identical to E. coli TolC is considered a TolC homolog.
  • a functional outer membrane protein that is at least 95% identical to TolC except for the replacement/addition of leader sequences, C-terminal sequences or other modifications intended to increase its functionality in a particular environment (e.g., a non-native host) are also considered functional homologs of TolC.
  • the same definitions apply to other protein homologs referred to herein.
  • a chimeric integral plasma membrane protein for facilitating alkane efflux in E. coli could be designed by fusing a pseudo leader sequence derived from E. coli or a related bacterium to a heterologous integral plasma membrane protein.
  • nucleic acid refers to a polymeric form of nucleotides of at least 10 bases in length.
  • the term includes DNA molecules (e.g. , cDNA or genomic or synthetic DNA) and RNA molecules (e.g., mRNA or synthetic RNA), as well as analogs of DNA or RNA containing non-natural nucleotide analogs, non-native internucleoside bonds, or both.
  • the nucleic acid can be in any topological conformation. For instance, the nucleic acid can be single-stranded, double-stranded, triple-stranded, quadruplexed, partially double-stranded, branched, hairpinned, circular, or in a padlocked conformation.
  • nucleic acid comprising SEQ ID NO: l refers to a nucleic acid, at least a portion of which has either (i) the sequence of SEQ ID NO: 1 , or (ii) a sequence complementary to SEQ ID NO: 1.
  • the choice between the two is dictated by the context. For instance, if the nucleic acid is used as a probe, the choice between the two is dictated by the requirement that the probe be complementary to the desired target.
  • RNA, DNA or a mixed polymer is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, e.g., ribosomes, polymerases and genomic sequences with which it is naturally associated.
  • an "isolated" organic molecule e.g., an alkane, alkene, or alkanal
  • an "isolated" organic molecule is one which is substantially separated from the cellular components (membrane lipids, chromosomes, proteins) of the host cell from which it originated, or from the medium in which the host cell was cultured.
  • the term does not require that the biomolecule has been separated from all other chemicals, although certain isolated biomolecules may be purified to near homogeneity.
  • the term “recombinant” refers to a biomolecule, e.g., a gene or protein, that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the gene is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature.
  • the term “recombinant” can be used in reference to cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems, as well as proteins and/or mRNAs encoded by such nucleic acids.
  • an endogenous nucleic acid sequence in the genome of an organism is deemed "recombinant” herein if a heterologous sequence is placed adjacent to the endogenous nucleic acid sequence, such that the expression of this endogenous nucleic acid sequence is altered.
  • a heterologous sequence is a sequence that is not naturally adjacent to the endogenous nucleic acid sequence, whether or not the heterologous sequence is itself endogenous (originating from the same host cell or progeny thereof) or exogenous (originating from a different host cell or progeny thereof).
  • a promoter sequence can be substituted (e.g., by homologous
  • a nucleic acid is also considered “recombinant” if it contains any modifications that do not naturally occur to the corresponding nucleic acid in a genome.
  • an endogenous coding sequence is considered “recombinant” if it contains an insertion, deletion or a point mutation introduced artificially, e.g., by human intervention.
  • a "recombinant nucleic acid” also includes a nucleic acid integrated into a host cell chromosome at a heterologous site and a nucleic acid construct present as an episome.
  • the phrase "degenerate variant" of a reference nucleic acid sequence encompasses nucleic acid sequences that can be translated, according to the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.
  • the term "degenerate oligonucleotide” or “degenerate primer” is used to signify an oligonucleotide capable of hybridizing with target nucleic acid sequences that are not necessarily identical in sequence but that are homologous to one another within one or more particular segments.
  • sequence identity refers to the residues in the two sequences which are the same when aligned for maximum correspondence.
  • the length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides.
  • polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wis.
  • FASTA provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. Pearson, Methods Enzymol. 183:63-98 (1990) (hereby incorporated by reference in its entirety).
  • percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOP AM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1 , herein incorporated by reference.
  • sequences can be compared using the computer program, BLAST (Altschul et al, J. Mol. Biol. 215:403-410 (1990); Gish and States, Nature Genet. 3:266-272 (1993); Madden et al, Meth. Enzymol. 266: 131-141 (1996); Altschul et al, Nucleic Acids Res. 25:3389-3402 (1997); Zhang and Madden, Genome Res. 7:649-656 (1997)), especially blastp or tblastn (Altschul et al, Nucleic Acids Res. 25:3389- 3402 (1997)).
  • nucleic acid or fragment thereof indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 76%, 80%, 85%, preferably at least about 90%, and more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.
  • nucleic acid or fragment thereof hybridizes to another nucleic acid, to a strand of another nucleic acid, or to the complementary strand thereof, under stringent hybridization conditions.
  • Stringent hybridization conditions and “stringent wash conditions” in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization.
  • stringent conditions are defined for solution phase hybridization as aqueous hybridization (i.e., free of formamide) in 6xSSC (where 20xSSC contains 3.0 M NaCl and 0.3 M sodium citrate), 1% SDS at 65°C for 8- 12 hours, followed by two washes in 0.2xSSC, 0.1% SDS at 65°C for 20 minutes. It will be appreciated by the skilled worker that hybridization at 65°C will occur at different rates depending on a number of factors including the length and percent identity of the sequences which are hybridizing.
  • nucleic acids also referred to as polynucleotides
  • the nucleic acids may include both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. They may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art.
  • Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, intemucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphorami dates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.) Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions.
  • uncharged linkages e.g., methyl phosphonates, phosphotriesters, phosphorami dates, carbamates, etc.
  • charged linkages
  • nucleic acid sequences include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.
  • modifications can include, for example, analogs in which the ribose ring contains a bridging moiety or other structure such as the modifications found in "locked" nucleic acids.
  • mutated when applied to nucleic acid sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus.
  • one or more alterations may be made at any number of loci within a nucleic acid sequence.
  • a nucleic acid sequence may be mutated by any method known in the art including but not limited to mutagenesis techniques such as "error-prone PCR" (a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product; see, e.g., Leung et ah, Technique, 1 : 1 1-15 (1989) and Caldwell and Joyce, PCR Methods Applic.
  • oligonucleotide-directed mutagenesis a process which enables the generation of site-specific mutations in any cloned DNA segment of interest; see, e.g., Reidhaar-Olson and Sauer, Science 241 :53-57 (1988)).
  • Attenuate generally refers to a functional deletion, including a mutation, partial or complete deletion, insertion, or other variation made to a gene sequence or a sequence controlling the transcription of a gene sequence, which reduces or inhibits production of the gene product, or renders the gene product non-functional. In some instances a functional deletion is described as a knockout mutation. Attenuation also includes amino acid sequence changes by altering the nucleic acid sequence, placing the gene under the control of a less active promoter, down-regulation, expressing interfering RNA, ribozymes or antisense sequences that target the gene of interest, or through any other technique known in the art.
  • the sensitivity of a particular enzyme to feedback inhibition or inhibition caused by a composition that is not a product or a reactant is lessened such that the enzyme activity is not impacted by the presence of a compound.
  • an enzyme that has been altered to be less active can be referred to as attenuated.
  • the term “deletion” refers to the removal of one or more nucleotides from a nucleic acid molecule or one or more amino acids from a protein, the regions on either side being joined together.
  • knock out refers to a gene whose level of expression or activity has been reduced to zero.
  • a gene is knocked-out via deletion of some or all of its coding sequence.
  • a gene is knocked-out via introduction of one or more nucleotides into its open reading frame, which results in translation of a non-sense or otherwise non-functional protein product.
  • vector as used herein is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid generally refers to a circular double stranded DNA loop into which additional DNA segments may be ligated, but also includes linear double-stranded molecules such as those resulting from amplification by the polymerase chain reaction (PCR) or from treatment of a circular plasmid with a restriction enzyme.
  • PCR polymerase chain reaction
  • Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC).
  • BAC bacterial artificial chromosome
  • YAC yeast artificial chromosome
  • Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome (discussed in more detail below).
  • vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., vectors having an origin of replication which functions in the host cell). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and are thereby replicated along with the host genome. Moreover, certain preferred vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors" (or simply "expression vectors").
  • “Operatively linked” or “operably linked” expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in trans or at a distance to control the gene of interest.
  • expression control sequence refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient R A processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g. , ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion.
  • control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence.
  • control sequences is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
  • recombinant host cell (or simply "host cell”), as used herein, is intended to refer to a cell into which a recombinant vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein.
  • a recombinant host cell may be an isolated cell or cell line grown in culture or may be a cell which resides in a living tissue or organism.
  • peptide refers to a short polypeptide, e.g., one that is typically less than about 50 amino acids long and more typically less than about 30 amino acids long.
  • the term as used herein encompasses analogs and mimetics that mimic structural and thus biological function.
  • polypeptide encompasses both naturally-occurring and non-naturally- occurring proteins, and fragments, mutants, derivatives and analogs thereof.
  • a polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different domains each of which has one or more distinct activities.
  • isolated protein or "isolated polypeptide” is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) exists in a purity not found in nature, where purity can be adjudged with respect to the presence of other cellular material (e.g., is free of other proteins from the same species) (3) is expressed by a cell from a different species, or (4) does not occur in nature (e.g., it is a fragment of a polypeptide found in nature or it includes amino acid analogs or derivatives not found in nature or linkages other than standard peptide bonds).
  • polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be “isolated” from its naturally associated components.
  • a polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.
  • isolated does not necessarily require that the protein, polypeptide, peptide or oligopeptide so described has been physically removed from its native environment.
  • polypeptide fragment refers to a polypeptide that has a deletion, e.g., an amino -terminal and/or carboxy -terminal deletion compared to a full-length polypeptide.
  • the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.
  • a “modified derivative” refers to polypeptides or fragments thereof that are substantially homologous in primary structural sequence but which include, e.g., in vivo or in vitro chemical and biochemical modifications or which incorporate amino acids that are not found in the native polypeptide. Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labeling, e.g., with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such
  • Radioactive isotopes such as I, P, S, and H
  • ligands which bind to labeled antiligands e.g. , antibodies
  • fluorophores e.g. , fluorophores
  • chemiluminescent agents e.g. , enzymes
  • antiligands which can serve as specific binding pair members for a labeled ligand.
  • the choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation.
  • Methods for labeling polypeptides are well known in the art. See, e.g. , Ausubel et ah, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2002) (hereby incorporated by reference).
  • fusion protein refers to a polypeptide comprising a polypeptide or fragment coupled to heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins.
  • a fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusions that include the entirety of the proteins of the present disclosure have particular utility.
  • the heterologous polypeptide included within the fusion protein of the present disclosure is at least 6 amino acids in length, often at least 8 amino acids in length, and usefully at least 15, 20, and 25 amino acids in length.
  • Fusions that include larger polypeptides, such as an IgG Fc region, and even entire proteins, such as the green fluorescent protein (“GFP") chromophore-containing proteins, have particular utility. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.
  • GFP green fluorescent protein
  • the term “antibody” refers to a polypeptide, at least a portion of which is encoded by at least one immunoglobulin gene, or fragment thereof, and that can bind specifically to a desired target molecule.
  • the term includes naturally-occurring forms, as well as fragments and derivatives.
  • Fragments within the scope of the term “antibody” include those produced by digestion with various proteases, those produced by chemical cleavage and/or chemical dissociation and those produced recombinantly, so long as the fragment remains capable of specific binding to a target molecule. Among such fragments are Fab, Fab', Fv, F(ab').sub.2, and single chain Fv (scFv) fragments.
  • Derivatives within the scope of the term include antibodies (or fragments thereof) that have been modified in sequence, but remain capable of specific binding to a target molecule, including: interspecies chimeric and humanized antibodies; antibody fusions; heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies (see, e.g., Intracellular Antibodies: Research and Disease
  • antibodies can be produced by any known technique, including harvest from cell culture of native B lymphocytes, harvest from culture of hybridomas, recombinant expression systems and phage display.
  • non-peptide analog refers to a compound with properties that are analogous to those of a reference polypeptide.
  • a non-peptide compound may also be termed a "peptide mimetic” or a "peptidomimetic.” See, e.g., Jones, Amino Acid and Peptide Synthesis, Oxford University Press (1992); Jung, Combinatorial Peptide and Nonpeptide Libraries: A Handbook, John Wiley (1997); Bodanszky et al., Peptide Chemistry— A Practical Textbook, Springer Verlag (1993); Synthetic Peptides: A Users Guide, (Grant, ed., W. H. Freeman and Co., 1992); Evans et al, J. Med. Chem.
  • a "polypeptide mutant” or “mutein” refers to a polypeptide whose sequence contains an insertion, duplication, deletion, rearrangement or substitution of one or more amino acids compared to the amino acid sequence of a native or wild-type protein.
  • a mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally-occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini.
  • a mutein may have the same but preferably has a different biological activity compared to the naturally-occurring protein.
  • a mutein has at least 85% overall sequence homology to its wild-type counterpart. Even more preferred are muteins having at least 90% overall sequence homology to the wild- type protein.
  • a mutein exhibits at least 95% sequence identity, even more preferably 98%, even more preferably 99% and even more preferably 99.9% overall sequence identity.
  • Sequence homology may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.
  • Amino acid substitutions can include those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs.
  • Examples of unconventional amino acids include: 4-hydroxyproline, ⁇ -carboxyglutamate, ⁇ - ⁇ , ⁇ , ⁇ -trimethyllysine, ⁇ - ⁇ - acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5- hydroxylysine, N-methylarginine, and other similar amino acids and imino acids ⁇ e.g., 4- hydroxyproline).
  • the left-hand end corresponds to the amino terminal end and the right-hand end corresponds to the carboxy-terminal end, in accordance with standard usage and convention.
  • a protein has "homology” or is “homologous” to a second protein if the nucleic acid sequence that encodes the protein has a similar sequence to the nucleic acid sequence that encodes the second protein.
  • a protein has homology to a second protein if the two proteins have "similar” amino acid sequences.
  • homology between two regions of amino acid sequence is interpreted as implying similarity in function.
  • Sequence homology for polypeptides is typically measured using sequence analysis software. See, e.g. , the Sequence Analysis Software Package of the Genetics Computer Group (GCG), University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wis. 53705. Protein analysis software matches similar sequences using a measure of homology assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap” and "Bestfit" which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild-type protein and a mutein thereof. See, e.g., GCG Version 6.1.
  • a preferred algorithm when comparing a particular polypeptide sequence to a database containing a large number of sequences from different organisms is the computer program BLAST (Altschul et al, J. Mol. Biol. 215:403-410 (1990); Gish and States, Nature Genet. 3:266-272 (1993); Madden et al., Meth. Enzymol. 266: 131 -141 (1996); Altschul et al, Nucleic Acids Res. 25:3389-3402 (1997); Zhang and Madden, Genome Res. 7:649-656 (1997)), especially blastp or tblastn (Altschul et al, Nucleic Acids Res. 25:3389-3402 (1997)).
  • the length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues.
  • database searching using amino acid sequences can be measured by algorithms other than blastp known in the art.
  • polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1.
  • FASTA provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. Pearson, Methods Enzymol. 183:63-98 (1990) (incorporated by reference herein).
  • percent sequence identity between amino acid sequences can be determined using FASTA with its default parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1 , herein incorporated by reference.
  • Specific binding refers to the ability of two molecules to bind to each other in preference to binding to other molecules in the environment.
  • “specific binding” discriminates over adventitious binding in a reaction by at least two-fold, more typically by at least 10-fold, often at least 100-fold.
  • the affinity or avidity of a specific binding reaction, as quantified by a dissociation constant is about 10 "7 M or stronger (e.g., about 10 "8 M, 10 "9 M or even stronger).
  • Percent dry cell weight refers to a measurement of hydrocarbon production obtained as follows: a defined volume of culture is centrifuged to pellet the cells. Cells are washed then dewetted by at least one cycle of microcentrifugation and aspiration. Cell pellets are lyophilized overnight, and the tube containing the dry cell mass is weighed again such that the mass of the cell pellet can be calculated within ⁇ 0.1 mg. At the same time cells are processed for dry cell weight determination, a second sample of the culture in question is harvested, washed, and dewetted. The resulting cell pellet, corresponding to 1 -3 mg of dry cell weight, is then extracted by vortexing in approximately 1 ml acetone plus butylated
  • hydroxytolune as antioxidant and an internal standard, e.g., «-eicosane.
  • Cell debris is then pelleted by centrifugation and the supernatant (extractant) is taken for analysis by GC.
  • flame ionization detection FID
  • «-Alkane concentrations in the biological extracts are calculated using calibration relationships between GC-FID peak area and known concentrations of authentic n- alkane standards. Knowing the volume of the extractant, the resulting concentrations of the n- alkane species in the extractant, and the dry cell weight of the cell pellet extracted, the percentage of dry cell weight that comprised «-alkanes can be determined.
  • region refers to a physically contiguous portion of the primary structure of a biomolecule. In the case of proteins, a region is defined by a contiguous portion of the amino acid sequence of that protein.
  • domain refers to a structure of a biomolecule that contributes to a known or suspected function of the biomolecule. Domains may be co-extensive with regions or portions thereof; domains may also include distinct, non-contiguous regions of a biomolecule. Examples of protein domains include, but are not limited to, an Ig domain, an extracellular domain, a transmembrane domain, and a cytoplasmic domain.
  • molecule means any compound, including, but not limited to, a small molecule, peptide, protein, sugar, nucleotide, nucleic acid, lipid, etc., and such a compound can be natural or synthetic.
  • Carbon-based Products of Interest include alcohols such as ethanol, propanol, isopropanol, butanol, fatty alcohols, fatty acid esters, wax esters; hydrocarbons and alkanes such as propane, octane, diesel, Jet Propellant 8 (JP8); polymers such as terephthalate,
  • compositions and pharmaceutical intermediates such as 7-aminodeacetoxycephalosporanic acid (7-ADCA)/cephalosporin, erythromycin, polyketides, statins, paclitaxel, docetaxel, terpenes, peptides, steroids, omega fatty acids and other such suitable products of interest.
  • 7-ADCA 7-aminodeacetoxycephalosporanic acid
  • erythromycin 7-aminodeacetoxycephalosporanic acid
  • polyketides such as statins, paclitaxel, docetaxel, terpenes, peptides, steroids, omega fatty acids and other such suitable products of interest.
  • Biofuel refers to any fuel that derives from a biological source.
  • Biofuel can refer to one or more hydrocarbons, one or more alcohols, one or more fatty esters or a mixture thereof.
  • Hydrocarbon The term generally refers to a chemical compound that consists of the elements carbon (C), hydrogen (H) and optionally oxygen (O). There are essentially three types of hydrocarbons, e.g., aromatic hydrocarbons, saturated hydrocarbons and unsaturated hydrocarbons such as alkenes, alkynes, and dienes. The term also includes fuels, biofuels, plastics, waxes, solvents and oils. Hydrocarbons encompass biofuels, as well as plastics, waxes, solvents and oils.
  • the nucleic acid molecule of the present disclosure encodes a polypeptide having the amino acid sequence of any of the protein sequences provided in SEQ ID NOs: 1-214.
  • the nucleic acid molecule of the present disclosure encodes a polypeptide sequence of at least 50%, 60, 70%, 80%, 85%, 90% or 95% identity to one of the protein sequences of SEQ ID NOs: 1-214 and the identity can even more preferably be 96%, 97%, 98%, 99%, 99.9% or even higher.
  • novel nucleic acid sequences useful for the recombinant expression of ABC efflux pump systems are provided, including the YbhG, YbhF,YbhS and YbhR variants listed in Table 20.
  • the invention also provides the engineered outer membrane proteins listed in Table 20 and the nucleic acid sequences encoding those proteins.
  • the present disclosure also provides nucleic acid molecules that hybridize under stringent conditions to the above-described nucleic acid molecules.
  • stringent hybridizations are performed at about 25°C below the thermal melting point (T m ) for the specific DNA hybrid under a particular set of conditions, where the T m is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe.
  • Stringent washing is performed at temperatures about 5°C lower than the T m for the specific DNA hybrid under a particular set of conditions.
  • Nucleic acid molecules comprising a fragment of any one of the above-described nucleic acid sequences are also provided. These fragments preferably contain at least 20 contiguous nucleotides. More preferably the fragments of the nucleic acid sequences contain at least 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or even more contiguous nucleotides.
  • the nucleic acid sequence fragments of the present disclosure display utility in a variety of systems and methods.
  • the fragments may be used as probes in various hybridization techniques.
  • the target nucleic acid sequences may be either DNA or RNA.
  • the target nucleic acid sequences may be fractionated (e.g. , by gel electrophoresis) prior to the hybridization, or the hybridization may be performed on samples in situ.
  • nucleic acid probes of known sequence find utility in determining chromosomal structure (e.g., by Southern blotting) and in measuring gene expression (e.g., by Northern blotting).
  • sequence fragments are preferably detectably labeled, so that their specific hydridization to target sequences can be detected and optionally quantified.
  • nucleic acid fragments of the present disclosure may be used in a wide variety of blotting techniques not specifically described herein.
  • nucleic acid sequence fragments disclosed herein also find utility as probes when immobilized on microarrays.
  • Methods for creating microarrays by deposition and fixation of nucleic acids onto support substrates are well known in the art. Reviewed in DNA Microarrays: A Practical Approach (Practical Approach Series), Schena (ed.), Oxford University Press (1999) (ISBN: 0199637768); Nature Genet.
  • enzyme activities can be measured in various ways. For example, the pyrophosphorolysis of OMP may be followed spectroscopically (Grabmeyer et al., (1993) J. Biol. Chem. 268:20299-20304). Alternatively, the activity of the enzyme can be followed using chromatographic techniques, such as by high performance liquid chromatography (Chung and Sloan, (1986) J. Chromatogr. 371 :71 -81). As another alternative the activity can be indirectly measured by determining the levels of product made from the enzyme activity. These levels can be measured with techniques including aqueous chloroform/methanol extraction as known and described in the art (Cf. M. Kates (1986) Techniques of Lipidology; Isolation, analysis and identification of Lipids. Elsevier Science Publishers, New York (ISBN:
  • LCMS liquid chromatography-mass spectrometry
  • HPLC high performance liquid chromatography
  • MALDI-TOF MS Matrix- Assisted Laser Desorption Ionization time of flight-mass spectrometry
  • NMR nuclear magnetic resonance
  • NIR near-infrared
  • vectors including expression vectors, which comprise the above nucleic acid molecules of the present disclosure, as described further herein.
  • the vectors include the isolated nucleic acid molecules described above.
  • the vectors of the present disclosure include the above- described nucleic acid molecules operably linked to one or more expression control sequences.
  • the vectors of the instant disclosure may thus be used to express an Aar and/or Adm polypeptide contributing to «-alkane producing activity by a host cell, and/or a chimeric efflux protein for effluxing «-alkanes and other hydrocarbons out of the cell.
  • host cells transformed with the nucleic acid molecules or vectors of the present disclosure, and descendants thereof, are provided.
  • these cells carry the nucleic acid sequences of the present disclosure on vectors, which may but need not be freely replicating vectors.
  • the nucleic acids have been integrated into the genome of the host cells.
  • the host cell comprises one or more AAR or ADM encoding nucleic acids which express AAR or ADM in the host cell.
  • the host cells of the present disclosure can be mutated by recombination with a disruption, deletion or mutation of the isolated nucleic acid of the present disclosure so that the activity of the AAR and/or ADM protein(s) in the host cell is reduced or eliminated compared to a host cell lacking the mutation.
  • microorganism includes prokaryotic and eukaryotic microbial species from the Domains Archaea, Bacteria and Eucarya, the latter including yeast and filamentous fungi, protozoa, algae, or higher Protista.
  • microbial cells and “microbes” are used interchangeably with the term microorganism.
  • Photoautotrophic organisms include eukaryotic plants and algae, as well as prokaryotic cyanobacteria, green-sulfur bacteria, green non-sulfur bacteria, purple sulfur bacteria, and purple non-sulfur bacteria.
  • Extremophiles are also contemplated as suitable organisms. Such organisms withstand various environmental parameters such as temperature, radiation, pressure, gravity, vacuum, desiccation, salinity, pH, oxygen tension, and chemicals. They include
  • hyperthermophiles which grow at or above 80°C such as Pyrolobus fumarii; thermophiles, which grow between 60-80°C such as Synechococcus lividis; mesophiles, which grow between 15-60°C and psychrophiles, which grow at or below 15°C such as Psychrobacter and some insects.
  • Radiation tolerant organisms include Deinococcus radiodurans.
  • Pressure -tolerant organisms include piezophiles, which tolerate pressure of 130 MPa.
  • Weight-tolerant organisms include barophiles.
  • Hypergravity e.g., >l
  • hypogravity e.g., ⁇ lg
  • Vacuum tolerant organisms include tardigrades, insects, microbes and seeds.
  • Dessicant tolerant and anhydrobiotic organisms include xerophiles such as Artemia salina; nematodes, microbes, fungi and lichens.
  • Salt-tolerant organisms include halophiles (e.g., 2-5 M NaCl) Halobacteriacea and Dunaliella salina.
  • pH-tolerant organisms include alkaliphiles such as Natronobacterium, Bacillus firmus OF4, Spirulina spp. (e.g. , pH > 9) and acidophiles such as Cyanidium caldarium, Ferroplasma sp. (e.g. , low pH).
  • Anaerobes which cannot tolerate 0 2 such as Methanococcus jannaschii; microaerophils, which tolerate some 0 2 such as Clostridium and aerobes, which require 0 2 are also contemplated.
  • Gas-tolerant organisms, which tolerate pure C0 2 include Cyanidium caldarium and metal tolerant organisms include metalotolerants such as Ferroplasma acidarmanus (e.g. , Cu, As, Cd, Zn), Ralstonia sp. CH34 (e.g., Zn, Co, Cd, Hg, Pb). Gross, Michael. Life on the Edge: Amazing Creatures Thriving in Extreme
  • Plants include but are not limited to the following genera: Arabidopsis, Beta, Glycine, Jatropha, Miscanthus, Panicum, Phalaris, Populus, Saccharum, Salix, Simmondsia and Zea.
  • Algae and cyanobacteria include but are not limited to the following genera:
  • Acanthoceras Acanthococcus, Acaryochloris, Achnanthes, Achnanthidium, Actinastrum, Actinochloris, Actinocyclus, Actinotaenium, Amphichrysis, Amphidinium, Amphikrikos, Amphipleura, Amphiprora, Amphithrix, Amphora, Anabaena, Anabaenopsis, Aneumastus, Ankistrodesmus, Ankyra, Anomoeoneis, Apatococcus, Aphanizomenon, Aphanocapsa,
  • Chrysocapsella Chrysochaete, Chrysochromulina, Chrysococcus, Chrysocrinus,
  • Chrysolepidomonas Chrysolykos, Chrysonebula, Chrysophyta, Chrysopyxis, Chrysosaccus, Chrysophaerella, Chrysostephanosphaera, Clodophora, Clastidium, Closteriopsis, Closterium, Coccomyxa, Cocconeis, Coelastrella, Coelastrum, Coelosphaerium, Coenochloris, Coenococcus, Coenocystis, Colacium, Coleochaete, Collodictyon, Compsogonopsis, Compsopogon,
  • Crateriportula Craticula, Crinalium, Crucigenia, Crucigeniella, Cryptoaulax, Cryptomonas, Cryptophyta, Ctenophora, Cyanodictyon, Cyanonephron, Cyanophora, Cyanophyta, Cyanothece, Cyanothomonas, Cyclonexis, Cyclostephanos, Cyclotella, Cylindrocapsa, Cylindrocystis, Cylindrospermum, Cylindrotheca, Cymatopleura, Cymbella, Cymbellonitzschia, Cystodinium Dactylococcopsis, Debarya, Denticula, Dermatochrysis, Dermocarpa, Dermocarpella,
  • Desmatractum Desmidium, Desmococcus, Desmonema, Desmosiphon, Diacanthos,
  • Diacronema Diadesmis, Diatoma, Diatomella, Dicellula, Dichothrix, Dichotomococcus, Dicranochaete, Dictyochloris, Dictyococcus, Dictyosphaerium, Didymocystis, Didymogenes, Didymosphenia, Dilabifilum, Dimorphococcus, Dinobryon, Dinococcus, Diplochloris,
  • Pseudoquadrigula Pseudosphaerocystis, Pseudostaurastram, Pseudostaurosira, Pseudotetrastram, Pteromonas, Punctastraata, Pyramichlamys, Pyramimonas, Pyrrophyta, Quadrichloris,
  • Quadricoccus Quadrigula, Radiococcus, Radiofilum, Raphidiopsis, Raphidocelis, Raphidonema, Raphidophyta, Peimeria, Rhabdoderma, Rhabdomonas, Rhizoclonium, Rhodomonas,
  • Rhodophyta Rhoicosphenia, Rhopalodia, Rivularia, Rosenvingiella, Rossithidium, Roya, Scenedesmus, Scherffelia, Schizochlamydella, Schizochlamys, Schizomeris, Schizothrix, Schroederia, Scolioneis, Scotiella, Scotiellopsis, Scourfieldia, Scytonema, Selenastram,
  • Sphaerellopsis Sphaerodinium, Sphaeroplea, Sphaerozosma, Spiniferomonas, Spirogyra, Spirotaenia, Spiralina, Spondylomoram, Spondylosium, Sporotetras, Spumella, Staurastram, Stauerodesmus, Stauroneis, Staurosira, Staurosirella, Stenopterobia, Stephanocostis,
  • cyanobacteria that can be engineered to express the recombinant described herein include members of the genus Chamaesiphon, Chroococcus, Cyanobacterium, Cyanobium, Cyanothece, Dactylococcopsis, Gloeobacter, Gloeocapsa, Gloeothece, Microcystis, Prochlorococcus, Prochloron, Synechococcus, Synechocystis, Cyanocystis, Dermocarpella, Stanieria, Xenococcus, Chroococcidiopsis, Myxosarcina, Arthrospira, Borzia, Crinalium, Geitlerinemia, Leptolyngbya, Limnothrix, Lyngbya, Microcoleus, Oscillatoria, Planktothrix, Prochiorothrix, Pseudanabaena, Spirulina, Starria, Symploca, Tricho
  • Green non-sulfur bacteria include but are not limited to the following genera:
  • Chlorofiexus Chloronema, Oscillochloris, Heliothrix, Herpeto siphon, Roseiflexus, and
  • Green sulfur bacteria include but are not limited to the following genera:
  • Purple sulfur bacteria include but are not limited to the following genera:
  • Rhodovulum Thermo chromatium, Thiocapsa, Thiorhodococcus, and Thiocystis
  • Purple non-sulfur bacteria include but are not limited to the following genera:
  • Aerobic chemolithotrophic bacteria include but are not limited to nitrifying bacteria such as Nitrobacteraceae sp., Nitrobacter sp., Nitrospina sp., Nitrococcus sp., Nitrospira sp., Nitrosomonas sp., Nitrosococcus sp., Nitrosospira sp., Nitrosolobus sp., Nitrosovibrio sp.;
  • colorless sulfur bacteria such as, Thiovulum sp., Thiobacillus sp., Thiomicrospira sp.,
  • Archaeobacteria include but are not limited to methanogenic archaeobacteria such as Methanobacterium sp., Methanobrevibacter sp., Methanothermus sp., Methanococcus sp., Methanomicrobium sp., Methanospirillum sp., Methanogenium sp., Methanosarcina sp., Methanolobus sp., Methanothrix sp., Methanococcoides sp., Methanoplanus sp.; extremely thermophilic S-Metabolizers such as Thermoproteus sp., Pyrodictium sp., Sulfolobus sp., Acidianus sp.
  • methanogenic archaeobacteria such as Methanobacterium sp., Methanobrevibacter sp., Methanothermus sp., Methanococcus sp
  • microorganisms such as, Bacillus subtilis, Saccharomyces cerevisiae, Streptomyces sp., Ralstonia sp., Rhodococcus sp., Corynebacteria sp., Brevibacteria sp., Mycobacteria sp., and oleaginous yeast.
  • Preferred organisms for the manufacture of n-alkanes according to the methods discloused herein include: Arabidopsis thaliana, Panicum virgatum, Miscanthus giganteus, and Zea mays (plants); Botryococcus braunii, Chlamydomonas reinhardtii and Dunaliela salina (algae); Synechococcus sp PCC 7002, Synechococcus sp. PCC 7942, Synechocystis sp.
  • PCC 6803 Thermosynechococcus elongatus BP-1 (cyanobacteria); Chlorobium tepidum (green sulfur bacteria), Chloroflexus auranticus (green non-sulfur bacteria); Chromatium tepidum and Chromatium vinosum (purple sulfur bacteria); Rhodospirillum rubrum, Rhodobacter capsulatus, and Rhodopseudomonas palusris (purple non-sulfur bacteria).
  • Yet other suitable organisms include synthetic cells or cells produced by synthetic genomes as described in Venter et al. US Pat. Pub. No. 2007/0264688, and cell-like systems or synthetic cells as described in Glass et al. US Pat. Pub. No. 2007/0269862.
  • suitable organisms include microorganisms that can be engineered to fix carbon dioxide bacteria such as Escherichia coli, Acetobacter aceti, Bacillus subtilis, yeast and fungi such as Clostridium Ijungdahlii, Clostridium thermocellum, Penicillium chrysogenum, Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pseudomonas fluorescens, or Zymomonas mobilis.
  • a suitable organism for selecting or engineering is autotrophic fixation of C0 2 to products. This would cover photosynthesis and methanogenesis. Acetogenesis, encompassing the three types of C0 2 fixation; Calvin cycle, acetyl-CoA pathway and reductive TCA pathway is also covered. The capability to use carbon dioxide as the sole source of cell carbon
  • an engineered cyanobacterium e.g., a Synechococcus or Thermosynechococcus species
  • Other preferred organisms include Synechocystis, Klebsiella oxytoca, Escherichia coli or Saccharomyces cerevisiae.
  • Other prokaryotic, archaeal and eukaryotic host cells are also encompassed within the scope of the present disclosure.
  • desired hydrocarbons and/or alcohols of certain chain length or a mixture thereof can be produced.
  • the host cell produces at least one of the following carbon-based products of interest: 1-dodecanol, 1- tetradecanol, 1 -pentadecanol, «-tridecane, «-tetradecane, 15: 1 «-pentadecene, «-pentadecane, 16: 1 «-hexadecene, «-hexadecane, 17: 1 «-heptadecene, «-heptadecane, 16: 1 «-hexadecen-ol, n- hexadecan-l-ol and «-octadecen-l-ol, as shown in the Examples herein.
  • the carbon chain length ranges from Cio to C 2 o. Accordingly, the disclosure provides production of various chain lengths of alkanes, al
  • the methods of the present disclosure include culturing host cells for direct product secretion for easy recovery without the need to extract biomass. These carbon- based products of interest are secreted directly into the medium. Since the disclosure enables production of various defined chain length of hydrocarbons and alcohols, the secreted products are easily recovered or separated. The products of the disclosure, therefore, can be used directly or used with minimal processing.
  • compositions produced by the methods of the disclosure are used as fuels.
  • Such fuels comply with ASTM standards, for instance, standard specifications for diesel fuel oils D 975-09b, and Jet A, Jet A-l and Jet B as specified in ASTM Specification D. 1655-68.
  • Fuel compositions may require blending of several products to produce a uniform product. The blending process is relatively straightforward, but the determination of the amount of each component to include in a blend is much more difficult.
  • Fuel compositions may, therefore, include aromatic and/or branched hydrocarbons, for instance, 75% saturated and 25% aromatic, wherein some of the saturated hydrocarbons are branched and some are cyclic.
  • the methods of the disclosure produce an array of hydrocarbons, such as C 13 -C 17 or C10-C15 to alter cloud point.
  • the compositions may comprise fuel additives, which are used to enhance the performance of a fuel or engine.
  • fuel additives can be used to alter the freezing/gelling point, cloud point, lubricity, viscosity, oxidative stability, ignition quality, octane level, and flash point.
  • Fuels compositions may also comprise, among others, antioxidants, static dissipater, corrosion inhibitor, icing inhibitor, biocide, metal deactivator and thermal stability improver.
  • EXAMPLE 1 Identification of a multi-subunit prokaryotic efflux pump capable of mediating the export of intracellular n-alkanes and n-alkenes
  • E. coli upon expression of ADM and AAR, not only produces hydrocarbons, mostly «-pentadecane and «-heptadecene, but also secretes them into the growth medium (Schirmer A et al. (2010) Science 329:559-562). This is because E. coli expresses one or more efflux pump(s), entirely absent in wild-type JCC138 (a cyanobacteria) and derivatives therefrom expressing ADM and AAR, described in, e.g., U.S. Pat. No. 7,794,969.
  • the one or more efflux pump(s) are capable of catalyzing the transport of hydrocarbons from inside the cell through the inner membrane, then through the periplasmic space, and then through the outer membrane into the bulk phase and/or cell surface.
  • This Example describes the identification of one such alk(a/e)ne efflux pump in E. coli.
  • RNA samples from the following four strains - each in replicate and each replicate before (Tl) and 3.5 hr after (T2) addition of 1 mM IPTG - were analyzed using Agilent E. coli arrays: (1) JCCl 169, E. coli BL21(DE3) carrying p DFDuet-l ::adm_PCC7942 (non- hydrocarbon producing control), (2) JCCl 170, E. coli BL21(DE3) carrying pCDFDuet- l : aar_PCC7942 ( «-alkanal-, «-alkanol-producing control strain), (3) JCC1214, E. coli
  • the invention provides each of these four engineered strains of E. coli. In another embodiment, the invention provides methods of culturing each of these four engineered strains of E. coli and determining the level of secreted «-alkanes and «-alkenes in the culture medium.
  • Table 1 Genes specifically up-regulated in JCC1214 and JCC1113 that are likely involved in a general stress response to intracellular hydrocarbon production, and were therefore excluded from further analysis.
  • IM inner membrane
  • OM outer membrane.
  • TetR-family transcriptional regulator 1 st gene of Broad (includes
  • IM inner membrane
  • OM outer membrane
  • EPS exopolysaccharide
  • ABC ATP-binding cassette.
  • ybiH and ybhG are notable in that (i) they are adjacent on the chromosome, (ii) they are of broad phylogenetic distribution (occurring in Pseudomonas), and, most importantly, (iii) are part of a cluster/operon of genes that encode a putative efflux pump of the ATP-binding cassette (ABC) superfamily.
  • ybiH encodes a TetR- family transcriptional regulator, and therefore almost certainly cannot be involved directly in hydrocarbon efflux.
  • altering ybiH expression can be used to modulate expression of the ybhGFSR operon.
  • ybhG encodes a polypeptide of the membrane fusion protein (MFP) family.
  • MFPs are periplasmic/extracellular subunits of multi-component efflux transporters that perform a diverse array of extrusion functions in both Gram-positive and Gram-negative prokaryotes, with substrates from heavy metal ions to whole proteins (Zgurskaya H et al. (2009) BBA 1794:794- 807).
  • MFPs are components of three major classes of bacterial efflux pumps: Resistance- Nodulation-cell Division (RND), ATP-Binding Cassette (ABC), and Major Facilitator superfamilies.
  • MFPs are known to mediate the interaction between inner membrane pump subunits and an outer membrane channel protein partner, such that substrates can be expelled from the cytosol and/or from the periplasmic space and/or from the inner membrane to the cell exterior in a seamless fashion.
  • ybhG is part of what appears to be operon, ybhGFSR, encoding all the components required of an ABC-family efflux pump i.e., the MFP (ybhG), the cytosolic ATP-hydrolysis subunit (ybhF), and the two inner membrane subunits (ybhS and ybhR) ( Figure 2) (Davidson A et al.
  • an outer membrane protein is known to function promiscuously with several different inner membrane/periplasm efflux pump components in the extrusion of a wide range of lipophilic species and is thus the most likely candidate for the outer membrane partner of the YbhGFSR complex.
  • OMP outer membrane protein
  • TolC the amino acid sequences of the 15 known and predicted MFS proteins of E. coli K12 MG1655 were compared, focusing in on the sequence of the loop joining the two a-helices of the coiled-coil domain that is one of the structural signatures of MFS proteins (Table 3).
  • FIG. 4 A schematic of the fully assembled YbhGFSR-TolC efflux pump is shown in Figure 4.
  • YbhG paralog Yhil also matches this consensus, suggesting that this MFP, too, interacts with TolC.
  • the MFPs known not to depend on TolC do not conform to this consensus sequence.
  • Yhil is encoded within an operon paralogous to ybhGFSR, yhil-rbbA-yhhJ, that encodes another uncharacterized ABC efflux system (rbbA encoding a putative ATP-hydrolyzing/IM subunit fusion and yhhJ the other IM protein).
  • rbbA encoding a putative ATP-hydrolyzing/IM subunit fusion and yhhJ the other IM protein.
  • AaeA is known to be TolC-independent (Van Dyk TK et al. (2004) J Bacteriol 186:7196-7204).
  • a loop between the coiled coil domain is considered "long” if it is >30 amino acids; short loops are of uniform size.
  • CusB lacks a conventional coiled-coil domain.
  • MFS membrane fusion
  • EXAMPLE 2 Recombinant expression of hydrocarbon ABC efflux pump systems in an n-alkane producing non-photosynthetic or photosynthetic microbe
  • Engineered photosynthetic microbes expressing ADM and AAR have been and continue to be engineered to express hydrocarbon ABC efflux pump systems, e.g., ybhG/ybhF/ybhS/ybhR/tolC and homologous variants thereof or (prophetically) yhil/rbbA/yhhJ/tolC and homologous variants thereof.
  • This Example describes the creation of some exemplary constructs and microbes for alk(a/e)ne production and secretion. Many other examples of constructs and strains are provided elsewhere, herein.
  • E. coli leader sequences of YbhG was replaced with a native JCC138 leader sequence associated with periplasmic localization; TolC had its E. coli leader sequence replaced with a native JCC138 leader sequence associated with outer membrane localization.
  • the cytosolic ATP-binding subunits e.g., YbhF
  • inner membrane subunits YbhPv/YbhS
  • a variety of standard standard promoters are used to drive expression of these efflux pump genes in the JCC138 host (see, e.g., U.S. Pat. App. No. 12/833,821 , filed July 9, 2010, and U.S. Pat. App. No. 12/876,056, filed September 3, 2010).
  • the DNA and protein sequences of the E. coli efflux pump components are shown in Table 4 and Table 5, respectively.
  • the resulting strains are compared relative to an otherwise unmodified JCC138 alkanogen control strain to demonstrate the improved ability of strains expressing recombinant hydrocarbon ABC efflux pump systems to extrude hydrocarbons, e.g., «-pentadecane and/or «-heptadecane, into the growth medium.
  • An exemplary native JCC138 leader sequence associated with periplasmic location that will be swapped into YbhG and Yhil includes the first 22 amino acids of periplasmically SYNPCC7002_A0578
  • An exemplary native JCC138 leader sequence associated with outer membrane location that will be swapped into TolC includes the first 25 amino acids of JCC138 TolC homo log SYNPCC7002_A0585 (http://www.ncbi.nlm.nih.gOv/protein/l 69884879):
  • the invention provides recombinant E. coli cells comprising a modification to a gene listed in Table 4, wherein said modification is selected from the group consisting of (1) a modification that eliminates or reduces the activity of the gene, wherein said modification includes a whole or partial deletion of the gene or a point mutation; and (2) a modification that increases expression of a gene listed in Table 4, wherein said modification includes an additional copy of the gene and/or expression of the gene from a stronger promoter than the native promoter.
  • the invention provides an engineeered cyanobacterium recombinantly expressing one or more genes listed in Table 4.
  • the engineered cyanobacterium further comprises recombinant genes for «-alkane biosynthesis, e.g., aar and/or adm genes, which render it capable of synthesizing increased levels of «-alkanes (and/or «-alkenes) relative to an engineered cyanobacterium lacking said recombinant genes for «-alkane biosynthesis.
  • recombinant genes for «-alkane biosynthesis e.g., aar and/or adm genes, which render it capable of synthesizing increased levels of «-alkanes (and/or «-alkenes) relative to an engineered cyanobacterium lacking said recombinant genes for «-alkane biosynthesis.
  • EXAMPLE 3 Construction of ADM-AAR expression vector and bacterial strains for alkane synthesis
  • pJexpress404TM was purchased from DNA 2.0 (Menlo Park, CA).
  • pJexpress404TM contains a high copy number pUC origin of replication, the bla gene for carbenicillin/ampicillin resistance, a multiple cloning site, a modified T5 promoter for high expression and tight transcriptional control, and lacl as a repressor of the modified T5 promoter, adm (gene Synpcc7942_1593) and aar (gene
  • Synpcc7942_1594 of Synechococcus elongatus PCC 7942 were cloned as an operon from pJB853 into pJexpress404 to generate pJB1440.
  • the sequence of pJB1440 is presented in Table 6, below.
  • a fadE knockout strain in E. coli BW25113 (an E. coli K12 strain) which contains a kanamycin marker in place of fadE was obtained from the Yale strain collection (http://cgsc.biology.yale.edu; New Haven, CT). This marker was removed using pCP20TM which expresses a FLP recombinase vector as previously described (Datsenko et ah, PNAS (2000) 97:6640-5) to yield strain JCC1880 (E. coli W25U3AfadE).
  • PI transduction was used to transduce the knockout (kanamycin marker in place of targeted gene for knockout) from a donor strain of the Yale strain collection to the E. coli production strain JCC1880 (BW251 l3AfadE).
  • the derivative knockout strains were then transformed with the alkane production vector pJB1440 to express adm-aar.
  • JCC1880 derivative strains with the following genotypes were prepared:
  • Each of these strains was cultured in minimal media + 3% glucose + 30 mg/L FeCi3-6H 2 0 at 37°C, 250 rpm for 24 hours.
  • Expression of the adm-aar operon was induced from the T5 promoter with 1 mM IPTG at an OD 6 oo of about 0.4 (approximately six hours after inoculation).
  • the cells were harvested and cell- free supernatant samples were obtained after 18 hours of induction.
  • Cell pellets were extracted with acetone and supernatants with ethyl acetate. Measurements were taken by GC- FID.
  • Figure 6 confirms that inactivation of YbiH expression promotes alkane secretion (see Figure 6A and Figure 6B; compare AybiH to JCC1 1880). Figure 6 also confirms that constitutive expression of the YbhGFSR transporter increases secretion (see Figure 6A and
  • Figure 6B compare ybiH::Kan to JCC1180 and AybiH), with 40% of total alkanes being secreted into the supernatant. This level of secretion efficiency occurs in the absence of any agents added to the growth medium which are known to affect membrane permeability (e.g., Tris buffer, EDTA, Triton X-100 detergent and other surfactants).
  • Figure 6C and Figure 6D show that cell growth is inhibited when cells produce alkanes in the absence of a transporter capable of efficiently transporting alkanes, e.g., TolC or the YbhGFSR transporter.
  • Kanamycin promoter and gene coding sequence SEQ ID NO:36
  • EXAMPLE 4 Overexpression of ybhGFSR in E. coli improves alkane efflux
  • Plasmid pJB1932 containing the ybhGFSR operon under control of an inducible promoter
  • plasmid pCDFDuet-1 EMD4Biosciences
  • AscI and Mlul Mlul to remove a T7 promoter and the 5 ' end of lacl present on pCDFDuet- 1.
  • the remaining plasmid backbone containing the CLODF 13 origin, truncated lacl, and aadA (encoding spectinomycin resistance) was gel purified and self-ligated together using NEB Quick Ligase.
  • plasmid was then digested with restriction enzymes Notl and Ndel to serve as an open vector for insertion of a tetracycline-inducible promoter (Puetoi).
  • a tetR-Vueto insert was isolated by digestion of pJB800 (DNA 2.0) with Ndel and Notl followed by agarose gel purification. This insert was then ligated into the open vector cut with the same enzymes to create plasmid pJB 1918. Following construction of pJB 1918, the ybhGFSR operon was amplified by PCR from is.
  • the resulting PCR product was column purified, digested with Ndel and Fsel and ligated into plasmid pJB1918 also digested with Ndel and Fsel to create pJB1932.
  • Plasmids pJB 1932 (F Uet0 -i-ybhGFSR) and pJB 1440 (F(TS)-adm-aar) were co- transformed into JCC1880 (AfadE) by electroporation and transformants were isolated on LB agar plates containing carbenicillin (100 ⁇ g/ml) and spectinomycin (50 ⁇ g/ml).
  • plasmids pJB1918 and pJB 1440 were co-transformed into JCC2359 (AfadEAybhGFSR) to serve as a negative control strain. 2 unique, single colonies for each strain were picked to inoculate two 3-ml LB seed cultures in test tubes (containing appropriate antibiotics), which were incubated at 37°C and 260 rpm for ⁇ 16 hours.
  • EXAMPLE 5 Improved efflux of alkanes and alkenes in strains with a genetically disrupted lipopolysaccharide (LPS) layer
  • rfaC encoding ADP-heptose:LPS heptosyl transferase I
  • JCC1880 AfadE
  • a knockout cassette was constructed by amplification of a kanamycin marker from pKD13 (obtained from the Coli Genetic Stock Center, http://cgsc.biology.yale.edu/GDK.php) using Phusion HF DNA polymerase and primers KS140 (5'
  • the PCR product generated here contains a constitutively expressed kanamycin resistance marker flanked by 2 regions of homology, HI and H2, which flank the rfaC ORF in the E. coli genome.
  • Electrocompetent cells of JCC1880 harboring pKD46 and actively expressing Red Recombinase were transformed with 300 ng of purified PCR product and transformants were isolated isolated on LB agar plates containing 50 ⁇ g/ml kanamycin at 37°C.
  • JCC1880_r aC: :kan was transformed with pCP20 and cultured as previously described
  • Plasmids pJB 1932 (F Uet0 - i-ybhGFSR) and pJB 1440 (F(TS)-adm-aar) were co- transformed into JCC1880 (AfadE) and JCC1999 by electroporation. Transformants were isolated on LB agar plates containing carbenicillin (100 ⁇ g/ml) and spectinomycin (50 ⁇ g/ml). 2 unique, single colonies for each strain were picked to inoculate two 3-ml LB seed cultures in test tubes (containing appropriate antibiotics), which were incubated at 37°C and 260 rpm for ⁇ 16 hours.
  • genes and their corresponding enzymes involved in LPS layer synthesis or maintenance can be knocked out, mutated, or otherwise attenuated to achieve a similar effect (i.e., increased secretion of alkanes and alkenes relative to the parent strain).
  • Exemplary genes are listed in Table 10B.
  • the alkane producing strain is other than E. coli, homologs of these genes can be easily identified, then knocked out or mutated.
  • genes involved in the biosynthesis and maintenance of those layers can identified, then knocked out or mutated to diminish their activity, disrupt the layer of interest, and improve the efflux of hydrocarbons (alkanes, alkenes, etc.) produced by the modified microbe.
  • hydrocarbons alkanes, alkenes, etc.
  • This Example shows that the recombinant expression of an acetyl-CoA carboxylase operon leads to increased alkanes secretion by alkane-producing photosynthetic microbes.
  • the aadA promoter and gene sequence were designed to confer spectinomycin and streptomycin resistance to the integrated construct. Downstream of the UHR region restriction endonuclease recognition sites were inserted for Notl, Ndel and EcoRI, as well as the sites for BamHI, Xhol, Spel and Pad. Following the EcoRI site, the natural terminator from the alcohol dehydrogenase gene from Zymomonas mobilis (adhll) terminator was included. Convenient Xbal restriction sites flank the UHR and the DHR allowing cleavage of the DNA intended for recombination from the rest of the vector.
  • pJB373 was constructed by contract synthesis from DNA2.0 (Menlo Park, CA). To construct pJB525, the aadA promoter and gene in pJB373 were replaced with the npt promoter and gene using Pad and Ascl, thus conferring kanamycin resistance to the integrated construct.
  • transformation plasmid, pJB540, ⁇ trc)-accADBC was cloned into the Notl and EcoRI sites of pJB525.
  • a promoterless cassette was engineered by removing the Iacl-P(trc) cassette from pJB540 with Notl and Ndel, blunting the ends with Klenow, and self-ligating to make pJB1623.
  • V(psaA) and the ammonia-repressible nitrate reductase promoters, V(nir07) and V(nir09), were obtained from Genbank, and cloned between Notl and Ndel sites immediately upstream of accADBC in pJB540 to make pJB1624, 1625, and 1626, respectively.
  • Final transformation constructs are listed in Table 11. All restriction and ligation enzymes were obtained from New England Biolabs (Ipswich, MA).
  • pJB 1623- 1626 constructs were transformed into NEB 5-a competent E. coli (High Efficiency) (New England Biolabs: Ipswich, MA).
  • JCC2055 Plasmid transformation into JCC2055.
  • the constructs as described above were integrated onto the genome of JCC2055 (JCC138 pAQ3::P( «z>07)_adm_aar_spec R ), which is maintained at approximately 7 copies per cell.
  • the following protocol was used for integrating the DNA cassettes. Genomic DNA was isolated from strains containing the ⁇ 0358: accADBC insert using Epicentre Masterpure DNA purification kit (Madison, WI). JCC2055 was grown in an incubated shaker flask at 37°C at 1% C0 2 to an OD730 of 0.6 in A + medium supplemented with 200 ⁇ g/mL spectinomycin.
  • Table 13 Alkane production and efflux by various strains JCC3199 9.55 ⁇ 0.05 79.58 ⁇ 2.00 0.88 ⁇ 0.01 1.10 ⁇ 0.02
  • JCC3200 10.20 ⁇ 0.04 75.04 ⁇ 0.49 2.09 ⁇ 0.15 2.71 ⁇ 0.17
  • EXAMPLE 7 Increased extracellular alkanes in JCC2055 strains expressing YbhGFSR and A0585ProNterm TolC
  • the cultures were incubated in 125 ml flasks in a Multitron II (Infors) shaking incubator (37 °C, 150 rpm, 2 % C0 2 /air, continuous light) for 4-7 days.
  • a Multitron II (Infors) shaking incubator 37 °C, 150 rpm, 2 % C0 2 /air, continuous light
  • water was added to compensate for evaporation loss (based on measured mass loss of flasks from beginning to end of experiment assuming no dodecane evaporated) and 50 ⁇ of culture was removed for OD730S determination. 500 ⁇ of the cultures was removed and cell pellets obtained through centrifugation for quantification of cell-associated alkanes.
  • the supernatants were discarded and the cells resuspended in 1 ml of milli-Q water and transferred to a new microcentrifuge tube to remove contaminating DBE solution.
  • the cells were pelleted twice more and the supernatants discarded after each spin to remove residual water.
  • the cell pellets were vortexed for 20 seconds in 500 ⁇ of acetone (Acros Organics 326570010) containing 25 mg/L butylated hydroxytoluene and 25 mg/L eicosane (ABE solution).
  • the cellular debris was pelleted by centrifugation and the acetone supernatants were analyzed for the presence of 1-alkenes.
  • the remaining culture containing the dodecane overlay was pelleted by centrifugation and samples of the DBE were removed for quantification of medium-associated alkanes. Both ABE and DBE samples were submitted for quantification of pentadecane by GC/FID. The cell pellet and medium associated pentadecane concentration for each strain and flask were then normalized to the internal standard (eicosane) and reported as mg/L of culture. The strains bearing the transporter complex show an increased percentage of secreted pentadecane in the medium when compared to the control strain which produced a similar titre of pentadecane ( Figure 8).
  • the percentage of alkanes secreted by engineered photosynthetic microbes comprising a recombinant YbhGFSR efflux pump and recombinant OMP is at least two fold higher than that secreted by an otherwise identical strain lacking these recombinant proteins. In certain cases, the percentage of secreted alkanes is increased at least three, four or five fold in the engineered strains comprising the recombinant efflux pump/OMP relative to otherwise identical strains lacking the pump. Alkane secretion levels greater than 5%, greater than 10%, greater than 15% and /or between 5 and 20% and/or between 10 and 20% were observed in this experiment in strains comprising recombinant efflux pump/OMP proteins.
  • JCC Joule Culture Collection
  • JCC2055 is JCC138 (Synechococcus sp. PCC 7002) bearing on the endogenous high- copy plasmid pAQ3 a nitrate-inducible/urea-repressible promoter, P(nir07), a synthetic fragment derived from the nirA promoter of Synechococcus elongatus PCC 7942, directing the transcription of a codon- and restriction-site-optimized synthetic adm-aar operon encoding the alkanal deformylative monooxygenase (Adm; cce_0778) and acyl-acyl-carrier-protein (acyl- ACP) reductase (Aar; cce_1430) proteins from Cyanothece ATCC 51142.
  • JCC2055 The adm-aar operon in JCC2055 is linked to a downstream spectinomycin-resistance marker cassette ⁇ aadA), and the strain is fully segregated as determined by PCR.
  • JCC2055 was generated by transforming JCC138 with plasmid pJB1331 , a synthetic double-crossover recombination vector bearing upstream and downstream homology regions flanking the heterologous V rm01)-adm-aarlaadA cassette, targeting said cassette to the intergenic region between the convergently transcribed genes SYNPCC7002 C0006 and SYNPCC7002 C0007 on pAQ3.
  • the DNA sequence of pJB1331 is shown in SEQ ID NO:52.
  • >95% of the «-alkane synthesized by JC2055 are found to be cell-associated, almost certainly being located within the cytosol, i.e., ⁇ 5% of the «-alkane is found to be growth-medium-associated in this strain.
  • Tripartite pumps are energetically driven by either the proton-motive force across the inner membrane or by the ATP hydrolytic activity associated with the cytosolic moiety of the inner membrane component, and catalyze the active efflux of substrates from either the periplasmic space and/or cytosol beyond the outer membrane.
  • the tripartite efflux pump selected for expression in JCC2055, the TolC-YbhGFSR complex, and homologous variants thereof, is of the ATP-hydrolytic variety, its subunits being encoded by the ybhG-ybhF-ybhS-ybhR (ybhGFSR) operon and tolC gene of Escherichia coli K- 12, or homologous operons and genes, respectively, thereof.
  • ybhG encodes the periplasmic membrane fusion protein subunit(s), ybhF the cytosolically located ATP-hydrolyzing subunit(s) of the inner membrane component encoded by the paralogous integral membrane proteins encoded by ybhS and ybhR, and tolC the outer membrane protein (OMP - when genie, referred to as omp) subunit(s) known to partner with many different periplasmic/inner membrane efflux pumps in E. coli.
  • One class of efflux pump constructs integrated into JCC2055 consist of an omp transcriptional unit, V ⁇ -omp, adjacent to, and divergently transcribed from, aybhGFSR operonic transcriptional unit, V2-ybhGFSR, wherein PI and P2 indicate specific promoters independently driving transcription of omp and ybhGFSR, respectively, the P1 -P2 unit being referred to as the divergent promoter.
  • P 1 and P2 promoters are defined so as to include not only the promoter region itself, but also any and all additional downstream sequence up to the first base pair of the start codon of the associated ORF.
  • omp typically refers to one of a multitude of possible variants of the OMP pump component
  • ybhGFSR typically refers to one of a multitude of possible variant YbhG/YbhF/YbhS/YbhR complements.
  • an antibiotic-resistance cassette Associated with these divergently transcribed omp-Vl -Pl-ybhGFSR constructs is an antibiotic-resistance cassette, different from aadA, to permit selection of trans formants.
  • Flanking the omp- ⁇ -P2-ybhGFSRIm&rkQr cassette are upstream and downstream homology regions used for recombinationally integrating linked constructs into the JCC2055 chromosome.
  • the encoded OMP is E. coli TolC, or a homolog thereof.
  • the encoded OMP is either the TolC homolog of JCC138, SYNPCC7002 A0585 or the TolC homolog of
  • the encoded YbhG is one of several different homologous variants with specifically modified coiled-coil regions designed to promote functional interaction between the YbhGFSR component and either SYNPCC7002 A0585 or E. coli TolC, or a homolog thereof, encoded by the partner omp gene.
  • the second class of efflux pump constructs integrated into JCC2055 consists of a V2-ybhGFSR transcriptional unit integrated at one locus (linked to a unique antibiotic-resistance marker) of the JCC2055 chromosome and a PI -omp transcriptional unit at another, separate, locus of the JCC2055 chromosome (also linked to a unique antibiotic- resistance marker); in some cases, V ⁇ -omp corresponds to the wild-type SYNPCC7002_A0585 locus, i.e., native promoter plus native coding sequence.
  • amtl -downstream locus referred to as the amtl -downstream locus.
  • Homology regions and omp-V ⁇ -V2-ybhGFSR cassette were harbored on an E. coli vector backbone derived from pJ208 (DNA2.0; Menlo Park, CA).
  • the sequence of the homology regions and vector backbone, minus the omp-V ⁇ -P2-ybhGFSR cassette, whose insertion site is indicated by a dash, is shown in SEQ ID NO: 55.
  • the omp gene for all 14 amtl -downstream-targeted divergent omp-V ⁇ -?2-ybhGFSR pump constructs was either the native tolC gene from is. coli K-12 substr. MG1655 (E. coli
  • the three E. coli tolC variants differ in their encoded cleavable N-terminal signal sequence: either (1) the natural E. coli signal sequence of TolC, (2) the predicted signal sequence of the JCC138 TolC homolog SYNPCC7002_A0585 (A0585), or (3) the contiguous sequence encompassing both the predicted signal sequence and proline-rich N-terminal region of
  • SYNPCC7002_A0585 (A0585_ProNterm), was employed. Only one ybhGFSR operon was used for all 14 amii-downstream-targeted divergent tolC-? ⁇ -V2-ybhGFSR pump constructs: the native ybhGFSR operon from E. coli MG1655 (the native ybhG start codon being changed from GTG to
  • DNA sequences of each of the 14 fully assembled, chromosomally integrated constructs can be generated by concatenating, in the following order, (1) the appropriate tolC variant DNA sequence in reverse complementary orientation with respect to the indicated DNA sequence, (2) the appropriate P1-P2 divergent promoter (containing the internal kan marker) in the orientation corresponding to the indicated DNA sequence, and (3) the native E.
  • Table 15 Summary of the 14 amtl -downstream-targeted divergent omp-? ⁇ -?2-ybhGFSR efflux pump constructs transformed into JCC2055.
  • the DNA sequences of the indicated omp genes, P1-P2 promoters, and ybhGFSR operon are detailed below.
  • the sequence of the homology regions and vector backbone, minus the omp-Vl-Vl-ybhGFSR cassette, whose insertion site is indicated by a dash, is provided in SEQ ID NO:76.
  • the AA0358-targted omp-V ⁇ -P2-ybhGFSR pump constructs possess a gentamycin- resistance (aacCl) transformant selection marker situated downstream of, and transcribed in the same direction as, the ybhGFSR operon.
  • omp gene variants used for the AA0358-targeted divergent omp-V ⁇ -V2- ybhGFSR pump constructs were either a restriction- and codon-optimized version of the E. coli MG1655 tolC, tolC_opt, or one of three derivatives of this gene modified in the 5' region.
  • the four codon-optimized tolC variants differ in their encoded cleavable (codon-optimized) N- terminal signal sequence: either (1) the predicted signal sequence of SYNPCC7002_A0585 (A0585), (2) the predicted signal sequence of the JCC138 OMP85/BamA homolog
  • SYNPCC7002 A0318 (A0318), (3) the contiguous sequence encompassing both the predicted signal sequence and proline-rich N-terminal region of SYNPCC7002_A0585
  • hybrid_A0585 the Synpcc7942_1761 ORF, corresponding to the TolC ho mo log in Synechococcus elongatus PCC 7942, with its two putative 24 amino acid encoded membrane-fusion-protein-interacting loop regions replaced with the corresponding regions of E. coli TolC, denoted as hybrid_1761.
  • the loop regions in question are those located between a-helices H3 and H4 and between a- helices H7 and H8 of E. coli TolC, using the nomenclature and X-ray crystallographic information of Koronakis V et al. (2000).
  • coli TorA a protein exported into the periplasm via the twin-arginine transport (TAT) system (TorA), (3) the predicted signal sequence of the JCC138 N-acetylmuramyl-L- alanine amidase SY PCC7002_A0578 (A0578), or (4) the predicted signal sequence of the JCC138 OMP85/BamA homolog SYNPCC7002 A0318 (A0318), was employed.
  • TAT twin-arginine transport
  • P1-P2 divergent promoter 22 different variants of the P1-P2 divergent promoter were employed for the each AA0358-targeted omp-V ⁇ -?2-ybhGFSR construct, some component P 1 and P2 promoters being selected from a panel of promoters known to be constitutively active in JCC138, and others being selected as naturally occurring P1-P2 divergent promoters (of unknown activity with respect to JCC138) in non-JCC138 cyanobacterial genomes. Each of these 22 P1-P2 divergent promoters was designed with symmetric terminal Ndel sites such that, during construct assembly in E.
  • coli via Ndel digestion and ligation, it could insert between the omp gene andybhGFSR operon in either orientation (i.e., complementary or reverse complementary) thereby generating 44 possible divergent promoter sequences driving a given omp-ybhGFSR base construct.
  • the structures of the omp-ybhGFSR constructs integrated at the ⁇ 0358 locus are summarized in Table 16; associated DNA and protein sequences are provided in SEQ ID NOs: 77-88.
  • the DNA sequences of each of the fully assembled, chromosomally integrated constructs can be generated by concatenating, in the following order, (1) the appropriate omp variant DNA sequence in reverse complementary orientation with respect to the indicated DNA sequence, (2) the appropriate P 1 -P2 divergent promoter in either complementary or reverse complementary orientation with respect to the indicated DNA sequence, (3) the appropriate ybhG variant in the orientation corresponding to the indicated DNA sequence, and (4) the appropriate ybhFSR variant DNA sequence in the orientation
  • AA0358-targeted omp-V ⁇ - V2-ybhGFSR constructs were combinatorially assembled to generate, at least theoretically, all 3,168 possible combinations of 6 omp variants, ybhG_opt variants, 3 ybhS_opt-ybhR_opt operon variants, and 44 divergent P1-P2 promoters.
  • Table 16 Summary of the AA0358-targeted divergent omp-V l -Vl-ybhGFSR efflux pump constructs transformed into JCC2055.
  • the DNA sequences of the indicated omp genes, P1 -P2 promoters, ybhG genes, and ybhFSR sub-operons are detailed below.
  • V ⁇ aphII)-P ⁇ aphIIy GCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGT (SEQ ID NO:96) TGTTTGTCGGTGAACGCTCTCTAC TAGAGTCACACTGGCTCACCTTCGGGTGGGC
  • cce_0538-cce_0539 TACAAAATATAAACATAATCTTCACATAAAAATCTTTACATAAAGCGTAATTCTA (SEQ ID NO:97) CTAACGACAGAAACAGGGTGCCTTATGTTAGCCTATAGTTAGATTTAGTCCATAT
  • alll697-alrl698 2 AGCCAGTACATCTGAATCAACATACTGGCGATGAGCCTGGTTCAGGTGACAAC TA (SEQ ID NO:100) GAAAATATTTGGAAGCGAGACCTTCAC TAAGTTCACATTTAAGATGTGGCTTGGT
  • tlll506-tlrl507 GTAGGTCTTATGCTTAGGATCAGCTTAGTTGATACCCAATGCAATAACTGTTGCT (SEQ ID NO:106) TTGGAGATTCTTAATTATTCTATAGGTTTGGGTTATCAATCTTTAGAGTTGTTTA
  • tll0460-tlr0461 2 CATTCGGTTCTTGGTAAAACCTGCTAGAGTGGCACTACAGCCCTTTCCAAGATAT (SEQ ID NO:107) ACAGTCCATCCAGGGGAGGTCTTTCTTCCCCAGAGGGCCTCTGGCGGTTTTGAGC
  • cce 1 144-cce 1145 2 TAGATCCTAAAGATACCACATTTGAAAGGTATGATGGTGATCCACCTGCACAACG (SEQ ID NO:108) TTAATTGTAAGCTAATGGTTATTGATTTTAAAAGTTGGGTTTTCTTTTACCCCAA
  • Table 17 Summary of the 22 divergent promoters used for ⁇ 0358 -targeted divergent omp-Fl- V2-ybhGFSR efflux pump constructs transformed into JCC2055.
  • the DNA sequence corresponding to the integrated P(tsr2412)- ybhGFSR construct corresponds to the tolC-V(psaA)-kan-V(tw2 ⁇ A2)-ybhG-ybhF-ybhS-ybhR assembly described in Table 15, except that the DNA sequence between the amtl -downstream upstream homology region and the 5' end of the kan cassette, i.e., that encompassing the
  • V(psaA)-to ⁇ C unit as well as 100 bp downstream of it, was entirely deleted.
  • the JCC2055- derived base strain bearing this kan- ⁇ mke,d V(tsr2 ⁇ 2)-ybhGFSR transcriptional unit was entirely deleted.
  • the DNA sequence corresponding to the base plasmid used to transform JCC2522 with the 31 V ⁇ -omp constructs corresponds to the sequence detailed above covering the ⁇ 0358- targeted homology regions and associated vector backbone, except that the approximately 70 bp between the ⁇ 0358 upstream homology region and the TnlO bidirectional terminator (itself upstream of the gentamycin-resistance cassette), has been replaced by the rho-independent transcriptional terminator BBa_B0015 (Registry of Standard Biological Parts;
  • the three different C-terminal tolC_opt variants differ in their encoded (non-cleaved) carboxyl terminal sequences: either (1) the native E. coli TolC terminal sequence was used, (2) it was replaced by the corresponding C-terminal residues of SYNPCC7002_A0585 (A0585C), or (3) it was replaced by the corresponding C- terminal residues of SYNPCC7002 A0318 (A0318C).
  • the rationale for the using the C-terminal modifications was that C-terminal residues are known to be important for proper insertion of certain OMPs into the outer membrane (Robert V et al. (2006).
  • each of the 31 fully assembled, chromosomally integrated V ⁇ -omp constructs can be generated by concatenating, in the following order, (1) the appropriate P 1 promoter in the orientation corresponding to the indicated DNA sequence and (2) the appropriate omp DNA sequence in the orientation corresponding to the indicated DNA sequence, and then situating the resulting bipartite sequence concatamer between the flanking invariant homology region/bidirectional terminator DNA sequences of the AA0358-downstream homologous recombination vector - minus the aforementioned 70 bp between the ⁇ 0358 upstream homology region and the TnlO bidirectional terminator - as was described for the constructs described in Table 16.
  • Table 18 Summary of the 31 AA0358-targeted PI -omp efflux OMP pump constructs transformed into JCC2522, a derivative of JCC2055 bearing a P(tsr2412)-jMG SR transcriptional unit integrated at the amtl -downstream locus.
  • the DNA sequences of the indicated PI promoters and omp genes are detailed below.
  • SYNPCC7002 A1723 (YbhG opt hpl), or to replace the entire hairpin and binding tip of YbhG with those of SYNPCC7002 A1723 (YbhG_opt_hp2), or to replace the binding tip sequence of YbhG with that of SYNPCC7002 A1723 (YbhG_opt_hp4).
  • a YbhG chimera was designed to contain the SYNPCC7002 A1723 hairpin and retain the binding tip and flanking coiled-coil heptads of YbhG (YbhG_opt_hp3); this YbhG variant may allow the YbhGFSR complex to span the periplasm and peptidoglycan of JCC138 to successfully dock with heterologously expressed E. coli TolC, or homologs thereof.
  • the structures of the omp- ybhGFSR constructs transformed into JCC2055 are shown in Table 19.
  • each of the fully assembled, chromosomally integrated efflux pump constructs can be generated by concatenating, in the following order, (1) the appropriate omp variant DNA sequence in reverse complementary orientation with respect to the indicated DNA sequence, (2) the appropriate P 1 -P2 divergent promoter in either complementary or reverse complementary orientation with respect to the indicated DNA sequence, (3) the appropriate ybhG hairpin variant in the orientation corresponding to the indicated DNA sequence, and (4) the appropriate ybhFSR variant DNA sequence in the orientation corresponding to the indicated DNA sequence, and then situating the resulting tetrapartite sequence concatamer between the flanking invariant homology region/bidirectional terminator DNA sequences of the ⁇ 0358 homologous recombination vector (SEQ ID NO: 76).
  • ⁇ 0358 -targeted omp-ybhGFSR constructs were designed to be able to be combinatorially assembled to generate, at least theoretically, all 14,784 possible combinations of 2 omp variants, 12 ybhG_opt variants (_hpl , _hp2, _hp4), 4 ybhS_opt-ybhR_opt operon variants, and 44 divergent P1-P2 promoters plus 15 omp variants, ybhG_opt variants (_hp3), 4 ybhS_opt-ybhR_opt operon variants, and 44 divergent P1-P2 promoters.
  • Table 20 indicates all possible functional combinations of the OMP, YbhG, YbhF, YbhS, and YbhR proteins to be expressed in JCC2055.
  • the appropriate combinations of OMP, YbhG, YbhF, YbhS, and YbhR are designed to lead to the formation of functional ABC efflux pumps capable of catalyzing efflux of intracellular «-pentandecane.
  • Table 20 Protein sequences forming functional OMP-YbhGFSR ABC efflux pump variants. "Set 1" OMP and YbhG variants are listed in the two upper left boxes, respectively; “Set 2" OMP and YbhG variants are listed in the two lower left boxes, respectively.
  • SYNPCC7002_A0585 NCBI Accession # YP 001733848.1 ; encoded naturally by JCC138
  • SYNPCC7002_A0585 NCBI Accession # YP 001733848.1 ; encoded naturally by JCC138
  • YbhGJipl YbhGJipl
  • YbhG_hp2 YbhG_hp4
  • TorA YbhGJipl TorA_YbhG_hp2
  • TorA_YbhG_hp4 A0318_YbhG_hpl , A0318_YbhG_hp2, A0318_YbhG_hp4,
  • A0578_YbhG_hpl A0578_YbhG_hp2, or A0578_YbhG_hp4.
  • A0585_ProNterm_TolC A0585_ProNTerm_TolC_A0318C, A0585_ProNTerm_TolC_A0585C, A0318_TolC, A0318_ProNTerm_TolC, A0318_ProNTerm_TolC_A0318C, or
  • A0318_ProNTerm_TolC_A0585C is to be paired with one of 8 possible YbhG variants: YbhG, TorA YbhG, A0578_YbhG, A0318_YbhG, YbhG_hp3, TorA_YbhG_hp3, A0318_YbhG_hp3, or A0578_YbhG_hp3.
  • Any given OMP/YbhG variant pair within each of the said sets can be functionally paired with YbhF - only one variant thereof, corresponding to the wild-type E. coli sequence - and one of three possible YbhS/YbhR paralog pairs: wild-type YbhS plus wild-type YbhR, sll0041_Nin_PLS_YbhS plus sll0041_Nin_PLS_YbhR, or slrl044_Nin_PLS_YbhS plus sir 1044_Nin_PLS_YbhR.
  • the OMP and YbhG protein sequences associated with Set 1 are provided in SEQ ID NOs: 174-186.
  • TorA, A0318, and A0578 prefixes indicate differences only in the cleavable N-terminal signal sequence relative to the native YbhG signal sequence; other than this signal sequence difference, all mature YbhG variants of the same hairpin subtype, e.g.,
  • YbhGJipl TorA YbhGJipl, A0318_YbhG_hpl, and A0578_YbhG_hpl , are of identical protein sequence. Also note that all mature YbhG variants of the hairpin subtypes hpl and _hp4 are >95% identical at the amino acid level. But note that all mature YbhG variants of the hairpin subtype _hp2 are ⁇ 60% identical at the amino acid level to those of either subtypes hpl or _hp4.
  • OMP and YbhG protein sequences associated with Set 2 are provided in SEQ ID NOs: 187-207. Note that A0585_TolC, A0585_TolC_A0318C, A0585_TolC_A0585C,
  • A0585_ProNterm_TolC A0585_ProNTerm_TolC_A0318C, A0585_ProNTerm_TolC_A0585C, A0318_TolC, A0318_ProNTerm_TolC, A0318_ProNTerm_TolC_A0318C, and
  • A0318_ProNTerm_TolC_A0585C all contain >95% of the entire mature (i.e., post signal sequence cleavage) TolC. Note, however, that neither Hybrid_A0585 nor Hybrid_1761 bears more than 35% identity at the amino acid level to TolC. Also, note that Hybrid_A0585 and Hybrid_1761 are only 42% identical at the amino acid level.
  • the TorA, A0318, and A0578 prefixes indicate differences only in the cleavable N-terminal signal sequence relative to the native YbhG signal sequence; other than this signal sequence difference YbhG, TorA YbhG, A0578_YbhG, and A0318_YbhG are of identical mature protein sequence. But note that mature YbhG and mature YbhG variants of the hairpin subtype _hp3 bear significant alignment-based discontiguity to one another at the amino acid level.
  • slrl044_Nin_PLS_YbhS contain the entire YbhS sequence, excluding its N-terminal methionine, and that both sll0041_Nin_PLS_YbhR and slrl044_Nin_PLS_YbhR contain the entire YbhR sequence, excluding its N-terminal methionine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention identifie des procédés et des compositions pour modifier des organismes photoautotrophes servant d'hôtes, de façon que lesdits organismes convertissent efficacement le dioxyde de carbone et la lumière en hydrocarbures, par exemple, n-alcanes et n-alcènes, les n-alcanes étant sécrétés dans le milieu de culture par l'intermédiaire de protéines de transport exprimées par des techniques recombinantes. En particulier, l'utilisation de ces organismes pour la production commerciale de n-alcanes et autres molécules apparentées est envisagée.
EP11825898.7A 2010-09-14 2011-09-14 Procédés et compositions pour le transport extracellulaire d'hydrocarbures biosynthétiques et autres molécules Withdrawn EP2616537A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38291710P 2010-09-14 2010-09-14
US41487710P 2010-11-17 2010-11-17
US41671310P 2010-11-23 2010-11-23
US201161478045P 2011-04-21 2011-04-21
PCT/US2011/051648 WO2012037288A2 (fr) 2010-09-14 2011-09-14 Procédés et compositions pour le transport extracellulaire d'hydrocarbures biosynthétiques et autres molécules

Publications (2)

Publication Number Publication Date
EP2616537A2 true EP2616537A2 (fr) 2013-07-24
EP2616537A4 EP2616537A4 (fr) 2014-04-30

Family

ID=45832227

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11825898.7A Withdrawn EP2616537A4 (fr) 2010-09-14 2011-09-14 Procédés et compositions pour le transport extracellulaire d'hydrocarbures biosynthétiques et autres molécules

Country Status (4)

Country Link
US (5) US20120077251A1 (fr)
EP (1) EP2616537A4 (fr)
AU (1) AU2011302092A1 (fr)
WO (2) WO2012037285A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955820B1 (en) 2009-07-09 2011-06-07 Joule Unlimited, Inc. Methods and compositions for the recombinant biosynthesis of n-alkanes
US7794969B1 (en) 2009-07-09 2010-09-14 Joule Unlimited, Inc. Methods and compositions for the recombinant biosynthesis of n-alkanes
WO2014018849A1 (fr) * 2012-07-26 2014-01-30 International Park Of Creativity Préparation de dispositifs biologiques et leur utilisation pour l'augmentation de la production de métabolites secondaires à partir de plantes
EP2877584A4 (fr) 2012-07-26 2016-03-30 Casa Luker S A Procedes pour augmenter la production de composes phenoliques a partir de thebroma cacao
WO2015168288A2 (fr) * 2014-04-30 2015-11-05 The Regents Of The University Of California Cellules hôtes modifiées ayant une tolérance aux α-oléfines
WO2016040649A1 (fr) * 2014-09-12 2016-03-17 Coffa Gianguido Microbes génétiquement modifiés pour la conversion biologique de matières carbonées en alcanes
US10741863B2 (en) * 2015-05-21 2020-08-11 University Of Georgia Research Foundation, Inc. Engineered photosynthetic organisms, photosynthetic electrodes including the engineered photosynthetic organisms, photosynthetic bioelectrochemical cells and photosynthetic fuel cells
WO2016210154A1 (fr) * 2015-06-26 2016-12-29 The Regents Of The University Of California Constructions de fusion en tant que vecteurs de surexpression de protéine
CN107435064B (zh) * 2016-05-27 2020-12-11 国投生物科技投资有限公司 小球藻培养中危害金藻的快速定量检测qPCR方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006137A2 (fr) * 2009-07-09 2011-01-13 Joule Unlimited, Inc. Procédés et compositions pour la biosynthèse recombinante des n-alcanes
US20110117618A1 (en) * 2009-07-09 2011-05-19 Joule Unlimited, Inc. Methods and Compositions for the Recombinant Biosynthesis of n-Alkanes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022239A1 (en) * 1999-03-19 2002-02-21 John Clark Lagarias Phytofluors as fluorescent labels
AU2006347573B2 (en) 2005-12-06 2013-01-17 Synthetic Genomics, Inc. Synthetic genomes
JP2009521229A (ja) 2005-12-23 2009-06-04 ジェイ．クレイグ ベンター インスティチュート 細胞又は細胞様システムへのゲノム若しくは部分ゲノムのインストール
DK2840131T3 (da) * 2006-05-19 2020-01-20 Genomatica Inc Fremstilling af fedtsyrer og derivater deraf
CN101617039A (zh) * 2006-10-20 2009-12-30 代表亚利桑那大学的亚利桑那校董会 经修饰的蓝细菌
JP5714230B2 (ja) * 2007-01-31 2015-05-07 フェネックス インコーポレイテッド 発現上昇のための細菌リーダー配列
US20100199548A1 (en) * 2007-07-06 2010-08-12 Ls9, Inc. Systems and methods for the production of fatty esters
KR101735549B1 (ko) * 2008-05-16 2017-05-16 알이지 라이프 사이언시스, 엘엘씨 탄화수소를 생산하기 위한 방법과 조성물
US8945184B2 (en) * 2009-03-13 2015-02-03 Spinal Simplicity Llc. Interspinous process implant and fusion cage spacer
WO2011017565A2 (fr) 2009-08-07 2011-02-10 Joule Unlimited, Inc. Procédés et compositions destinés à réguler la croissance de la contamination dans des cultures cellulaires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006137A2 (fr) * 2009-07-09 2011-01-13 Joule Unlimited, Inc. Procédés et compositions pour la biosynthèse recombinante des n-alcanes
US20110117618A1 (en) * 2009-07-09 2011-05-19 Joule Unlimited, Inc. Methods and Compositions for the Recombinant Biosynthesis of n-Alkanes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012037288A2 *

Also Published As

Publication number Publication date
US20150337016A1 (en) 2015-11-26
AU2011302092A1 (en) 2013-04-11
WO2012037288A9 (fr) 2012-12-06
WO2012037285A2 (fr) 2012-03-22
US20120077251A1 (en) 2012-03-29
US20140093923A1 (en) 2014-04-03
US20120135486A1 (en) 2012-05-31
EP2616537A4 (fr) 2014-04-30
WO2012037288A2 (fr) 2012-03-22
WO2012037288A3 (fr) 2012-06-28
WO2012037285A3 (fr) 2012-06-07
WO2012037288A8 (fr) 2012-05-10
US20130280780A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
AU2010246473B2 (en) Methods and compositions for the recombinant biosynthesis of N-alkanes
US8932872B2 (en) Methods and compositions for the recombinant biosynthesis of n-alkanes
US20140093923A1 (en) Methods and Compositions for the Extracellular Transport of Biosynthetic Hydrocarbons and Other Molecules
WO2010006312A2 (fr) Procédés et compositions pour produire des produits à base de carbone d'intérêt dans des micro-organismes
US9034629B2 (en) Recombinant synthesis of medium chain-length alkanes
US20150152438A1 (en) Recombinant Synthesis of Alkanes
US9029124B2 (en) Photoalkanogens with increased productivity
WO2013096475A1 (fr) Transport extracellulaire d'hydrocarbures biosynthétiques et d'autres molécules
WO2015200335A1 (fr) Microbes photosynthétiques obtenus par génie génétique et synthèse recombinante de produits à base de carbone
AU2012200694B2 (en) Methods and compositions for the recombinant biosynthesis of N-alkanes
WO2014194130A1 (fr) Procédés et compositions pour contrôler l'expression génique dans des organismes photosynthétiques
AU2013245545A1 (en) Methods and compositions for the recombinant biosynthesis of N-alkanes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130411

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140331

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/02 20060101ALI20140325BHEP

Ipc: C12N 9/04 20060101ALI20140325BHEP

Ipc: C12N 1/13 20060101ALI20140325BHEP

Ipc: C12N 1/00 20060101ALI20140325BHEP

Ipc: C12N 1/21 20060101AFI20140325BHEP

Ipc: C12N 1/19 20060101ALI20140325BHEP

Ipc: C12N 1/15 20060101ALI20140325BHEP

Ipc: C12N 1/11 20060101ALI20140325BHEP

Ipc: C07K 19/00 20060101ALI20140325BHEP

17Q First examination report despatched

Effective date: 20160310

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160721